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ABSTRACT 
 
 
REBECCA DIANE POWELL. Production of immunomodulatory proteins in 
glycine max for use in diagnostics and as therapeutics. (Under the direction of 
DR. KENNETH L. BOST) 
 
 
 Immunomodulatory proteins can be utilized in diagnostic assays, as 
tolerance therapies and in vaccine development.  In the following studies, we 
describe the expression, characterization and use of two such proteins from the 
soybean expression platform:  human thyroglobulin (hTG) and merozoite surface 
protein 119 (MSP119).   
 We characterize the 1% TSP expression of human thyroglobulin, the 
primary auto antigen in Hashimoto’s thyroid disease, in soybean.  Our laboratory 
successfully purifies this vital diagnostic analyte and indicates its biological 
equivalency to human-derived thyroglobulin.  Furthermore, we demonstrate the 
usefulness of soy-derived hTG in preventing and inhibiting the progression of 
Hashimoto’s thyroid disease in the murine model. 
 While unable to express MSP 119 at the same level in the soybean seed, 
we use the following studies to further characterize the expression constructs 
that generate the greatest success in producing a soy-derived protein and 
optimize the process that leads to the use of oral delivery in vaccine 
development. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 MUCOSAL IMMUNOLOGY 
 
In mammalian species, the majority of the immunological effort is focused at 
mucosal surfaces, with the greatest concentration of immunocytes being in the 
small intestine[1, 2].  This mucosal immune system serves to protect the body 
interior against invasive pathogens and accompanying antigens, as well as inhibit 
the invasion of commensal bacteria from the gut[3].  In addition, the mucosal 
immune system appears to be linked or common, indicating that an immune 
response at one mucosal surface will initiate responses at others [1, 3, 4].  Two 
potential outcomes, tolerance or a protective immune response, are possible, 
and regulating this response is the primary goal of oral immunomodulatory 
protein administration.   
 In a protective response, pathogenic bacteria and/or foreign antigens can 
be taken up by the mucosal system in several ways.  First, antigen can gain 
access directly to the bloodstream from the gut, going on to interact with 
peripheral T-helper cells and creating a systemic response[2].  More directly, 
antigen can be taken up by so-called microfold (M) cells, specialized cells in the 
follicle-associated epithelium (FAE) of the gut[1, 2, 5].  Unlike professional 
antigen presenting cells (APCs), M cells do not express MHC II and cannot 
activate naïve B or T –cells[6].  Rather, M-cells act as an antigen transport 
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system across the intestinal epithelium, allowing the antigen to access the APCs 
found within the Peyer’s patches[1, 2].  Alternatively, antigen can be sampled 
and taken up by myeloid Dendritic Cells (DCs).  DCs use their dendrite properties 
to extend between the tight junctions of the epithelium and sample the gut 
antigens directly[7, 8].  Antigen-loaded DCs then drain via the lymph to the 
mesenteric lymph nodes(MLN)[2], where antigen is presented to naïve B-cells 
and CD4+ T-cells[2, 8].  This induces T-cell differentiation to effector T-cells or T-
helper cells, which produce immunoglobulin A (IgA)inducing cytokines[9].  In turn, 
naïve B-cells are induced to maturation and differentiation into high affinity, 
specific IgA producing plasma cells by the effects of TGF-!, IL-4 and Il-10[2, 3, 
8].  Both B-cells and T-cells primed in the MLN migrate through the thoracic duct 
and peripheral bloodstream, finally accumulating in the mucosa[2, 10].  Targeting 
to mucosal surfaces in this manner is achieved by site-specific integrins on the 
cell surface, with addressins, or integrin receptors, expressed on vascular 
endothelial cells at mucosal surfaces (figure 1). 
 Alternatively, oral antigens can induce a tolerance response at the gut 
mucosa, in which a potentially harmful immune response is prevented or 
suppressed by a number of possible mechanisms which, in turn, elicit a non-
harmful response (figure 2)[11].  The gut mucosa is sampled for antigens in the 
same manner as described above.  However,  subsets of dendritic cells, 
plasmacytoid DCs (pDCs) and CD8" (+) DCs, are implicated in inducing a 
tolerance response via T-regulatory cells (Tregs) or clonal deletion, 
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respectively[11].  It is likely the differentiation to such a response is, in part, due 
to antigen detection and uptake in the small intestinal mucosa[12, 13].   
 Upon antigen uptake, these DC subsets migrate to the MLN, subsequently 
activating antigen-specific T cells, which are then deleted or differentiate into 
Tregs.  Newly differentiated Tregs migrate via the lamina propria through the 
thoracic duct and peripheral bloodstream to the gut mucosa, inhibit a Th1 
inflammatory response in the gut[14].  The antigen presenting DCs then migrate 
to the portal circulation.  Once in the liver, DCs activate natural killer T-cells and 
Kupffer cells.  The activity of these three cells types, with the production of IL-10 
and TGF-!, skew the liver’s resident T cells to a Treg differentiation.  Once these 
Tregs migrate through the portal vein to the body’s systemic circulation, the 
desired systemic tolerance response is achieved[11, 14, 15].  This mechanism is 
thought to be driven by small amounts or doses of a specific oral antigen[15]. 
 High dose antigen administration appears to be responsible for an anergic 
or clonal deletion response, in which T-cells are either unable to respond to the 
antigen or are activated and subsequently undergo apoptosis. 
 Anergy in T-cells is the result of the absence of one of the signals 
necessary to fully activate the cell.  Typically, a signal from both the T-cell 
antigen receptor (TCR) and the CD28 costimulatory ligand is required for 
activation and response to a particular antigen[16].  In response to these stimuli, 
the cell produces Il-2, a T-cell growth factor which promotes CD8+ T cell memory 
and the production of inflammatory cytokines[17, 18], thereby augmenting a T-
cell response.  During an anergic response, however, T-cells fail to produce Il-2 
 4 
in response to a stimulus, resulting in an abortive proliferative response and the 
deficient production of inflammatory cytokines[19].  While the mechanism of 
action is not fully elucidated, it is hypothesized that antigen presenting cells 
(APCs) that have failed to up-regulate costimulatory ligands (such as pDCs) are 
partially responsible for the lack of signal[17].  It is currently unclear why high 
doses of antigen initiate this pathway. 
 Alternatively, high dose antigen administration can lead to deletion of 
mucosal T-cells by apoptosis[15].   Apoptosis is induced in T-cells as a response 
to chronic TCR stimulation or cytokine deprivation[20, 21].  While a complete 
understanding of this mechanism has not yet been established, it is suggested 
that, upon T-cell activation, the survival cytokine Il-7 is down-regulated in the 
cell[22].  When presented with a weak, chronic stimulus, these cells are unable to 
respond and instead initiate apoptosis via the mitochondrial pathway[23].  
Additionally, Fas/Fas ligand induced, Bim-dependent apoptosis induced by 
cytokine deprivation is thought to be a mechanism by which Tregs destroy 
autoreactive immune cells[24]. 
 When these mechanisms, protective immunity and tolerance, fail; the body 
succumbs to infection and disease.   
 1.2 MALARIA 
The obligate intracellular parasite, Plasmodium, is the causative agent of malaria 
disease and is responsible for more than 2 million deaths each year.  The burden 
of disease is found predominantly in tropical regions of the developing world and 
is focused on the four major species that infect human hosts: P. ovale, P. vivax, 
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P. malariae and P. falciparum[33].  The parasite has an extremely complex 
lifecycle (figure 3), including both a vertebrate host and the Anopheles mosquito 
vector.  Initial infection is generated via transmission of sporozoite parasites from 
the mosquito salivary glands to the bloodstream of the victim.  Within minutes, 
these sporozoites migrate to the liver sinusoid, infecting hepatocytes and 
developing into mature asexual stage merozoites over the course of 5-10 
days[34].  During this time, the victim displays no symptoms of disease 
pathology[35].  The liver schizont then ruptures, releasing up to 30,000 merozoite 
parasites into the bloodstream.  This erythrocytic stage is responsible for disease 
pathology, including fever, anemia and blood vessel occlusion[36].  Additionally, 
merozoite proteins are exposed to the host immune system, while liver stage 
(pre-erythrocytic sporozoites) proteins are not.  Therefore, it is the blood stage 
infection which has become the central focus for disease therapy and vaccine 
development. 
 Upon release from hepatocytes, merozoite parasites seek to invade 
erythrocytes.  This invasion begins with initial contact between the merozoite 
surface and the erythrocyte membrane.  The merozoite surface reorients to the 
erythrocyte membrane, such that the apical end of the parasite binds the 
membrane[33].  The contents of the apical organelles (micronemes, rhoptries 
and dense granules) are released, forming a tight junction between the cell and 
the parasite[37].  The formation of such a tight junction is irreversible, and the 
parasite is then committed to erythrocyte invasion.  A series of proteolytic 
cleavages allows actual invasion of the erythrocyte by the merozoite and the 
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formation of the parasitophorous vacuole within the cell.  The membrane of the 
vacuole fuses to the erythrocyte membrane, completing the process[33, 37].  
Merozoite surface protein 1 (MSP 1) is a primary protein utilized during the 
invasion process, and its cleavage is required for successful erythrocyte 
infection.  MSP 1 is, as implied, a surface protein found on the merozoite 
parasite.  It ranges in size from 180-225kDa, depending upon the Plasmodium 
species, and is anchored to the surface via a C-terminal glycosyl-phosphatidyl-
inositol (GPI) moiety[38].  The first proteolytic cleavage occurs upon liver 
schizont rupture, resulting in a protein complex that includes the abbreviated 
MSP 1 fragment, MSP 1-42.  The second cleavage occurs during erythrocyte 
invasion.  The protein complex is released, and the C-terminal MSP 1-42 
fragment is cleaved, leaving the 11kDa MSP 1-19 fragment attached to the 
merozoite surface[38].  It is suggested that this cleavage is required for invasion 
due to the formation of a co-ligand between MSP 1-19 and MSP 9, another 
surface protein, which then binds the erythrocyte protein band, altering the 
erythrocyte membrane and allowing parasite entry[39].     
 MSP1-19 has become a primary vaccine target, unlike other fragments of 
MSP proteins that undergo cleavage, due to its rigid and highly conserved 
structure.  MSP 1-19 has two epidermal growth factor-like (EGF-like) domains in 
tandem.  These domains remain in contact and, together with invariant amino 
acid residues, generate an extremely rigid structure that resists polymorphisms.  
Additionally, this structure has been conserved across all Plasmodium species 
that infect the human host[40].  While no vaccine is currently available, a number 
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of studies involving both animal models and humans have demonstrated the 
efficacy and protection of anti-MSP1-19 antibodies, as well as their role in 
naturally acquired clinical immunity[41-43].  As such, it seems reasonable to 
suggest the successful malaria vaccine will contain this conserved element of 
MSP 1. 
1.3 HASHIMOTO’S THYROIDITIS 
While mammalian species, including humans, often succumb to disease related 
to pathogenic organisms, autoimmune disorders caused by the immune system’s 
inappropriate protective response to self antigens are equally common and 
detrimental.  These diseases can be a result of antibodies that react with host 
tissue or proteins, effector T cells which are specific for certain peptides and any 
number of supporting environmental and genetic factors[25].  Such autoimmune 
diseases are either systemic or organ specific.  Systemic disease results in a 
widespread immune response to a ubiquitous molecule, while an organ specific 
disease is characterized by chronic T-cell or antibody attack of a certain 
organ[26].  Approximately 4-5% of the general population is affected by some 
form of autoimmune disease, most of which are more prevalent in women[26, 
27].  Autoimmune thyroid disease represents over 30% of organ specific 
autoimmunity, and as such, is the most common archetype of disease, with 
Hashimoto’s thyroiditis (HT) being the most prevalent form, affecting over 1% of 
the general population[26].   
 Patients with HT present with a variety of clinical symptoms, including dry 
skin, hair loss, weight gain, fatigue, temperature intolerance and mental 
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slowing[26, 27].  Immunologically, symptoms are the result of the body’s failure to 
recognize the thyroid hormones, such as thyroglobulin, as self-antigens.  In such 
individuals, autoantibodies are present in the sera, which bind to thyroglobulin, 
activating CD4+ T-lymphocytes to degrade it.  This leads to decrease in thyroid 
function and, ultimately, complete thyroid destruction (figure 4)[28].  The reason 
for the breakdown in immune tolerance is unclear; however, multiple studies 
suggest a combination of factors.  Some studies report the implications of both 
MHC-HLA and CTLA-4 genes in development of susceptibility to autoimmune 
thyroiditis, but the mechanisms have not yet been elucidated.  Furthermore, the 
evidence is tenuous, as sample sizes have been small and offer conflicting 
data[26].  Additionally, monozygotic twin studies further suggest the effects of 
environmental triggers (albeit unknown), as one twin is often afflicted and the 
other is not[29].   
Currently, the only available treatment for this disease is the life long 
administration of the synthetic hormone replacement drug, levothyroxine 
sodium[30].  While this therapy can be effective, a narrow therapeutic dosing 
range must be determined for each individual and recalibrated as symptoms 
worsen[31, 32].  Ultimately, levothyroxine can control the symptoms of disease, 
but is unable to abrogate disease progression and thyroid destruction[27].   
1.4 VACCINES AND ORAL TOLEROGENS  
Vaccination is one of the most successful health interventions in human history.  
The first vaccination was performed over 200 years ago by Edward Jenner, when 
he inoculated a thirteen year-old boy with vaccinia virus (cowpox) to protect him 
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against variola virus (smallpox)[33].  Less than 100 years later, in 1885,  Louis 
Pasteur used a similar method to produce the world’s first widely used vaccine, 
against the virus that causes rabies[34, 35].  Since then, over 25 vaccines have 
been licensed for human use, including those against such scourges as 
poliomyelitis, diphtheria, pertussis, tetanus and influenzae[35].  While the 
greatest achievement in this area remains the eradication of smallpox, which was 
achieved in 1979, other vaccinations (including the ones previously listed) have 
led to the extension of life expectancy and the prevention of close to one million 
deaths each year[33, 35].  While such progress is impressive, the 22 new and 
reemerging diseases identified in the last 30 years underscore the necessity of 
improving vaccine development and seeking alternatives forms of 
vaccination[35].   
 Early vaccines were derived from live organisms.  These organisms were 
either chemically attenuated or heat inactivated and administered live or killed 
prior to inoculation.   This method of vaccine development is still seen today in 
such vaccines as the attenuated bacillus Calmette-Guerin (BCG) against 
tuberculosis, inactivated tetanus toxoid and the administrated of inactivated 
whole cell pertussis vaccine[34].  Live vaccines and inactivated toxoids, such as 
these, are highly immunogenic and, therefore, rarely require administration with 
an accompanying adjuvant to elicit a robust immune response[36].  Furthermore, 
the use of toxoids as carrier proteins allows conjugate vaccines to elicit an 
equally robust response.  Conjugate vaccines are derived from poorly 
immunogenic molecules, such as polysaccharides and small peptides, covalently 
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linked to more highly immunogenic molecules, such as toxoids and other large 
proteins.  Successful vaccines of this nature include H. influenzae type b and 
meningococcus[36].   
 More recently, vaccine manufacturing has shifted to produce alternative 
types of therapies.  Subunit vaccines are ideal in that they are easily generated in 
large quantities and can be safely reproduced.  They have no possibility of 
reversion and minimal cross-reactivity with human tissue, giving them an overall 
level of safety[34].    Subunit vaccines are produced via the identification of a 
highly immunogenic epitope or protein found in the infectious disease for which 
protection is desired.  This protein is then produced in bulk, utilizing recombinant 
DNA technology, and administered parentally with an appropriate adjuvant 
formulation, such as aluminum salt emulsions.   
 Recombinant DNA technology can also be used in the production of 
genome-based vaccinations.  Using live vectors, such as adenovirus or non-
pathogenic bacteria, recombinant proteins can be expressed and presented to 
the host immune system.  Such vectors can be further modified to express 
immunomodulatory cytokines, thereby skewing the immune response elicited by 
the host.  Additionally, DNA technology can be used to encode a eukaryotic 
promoter plasmid with the gene responsible for the immunogenic protein.  
Following vaccination with the plasmid, the promoter is activated and the gene of 
interest expressed, producing the antigen in situ[36].   
 While such vaccine strategies are successful, many of these technologies 
are extremely costly and beyond the reach of all but the wealthiest countries.  
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Additionally, in order to safely administer these types of vaccines, it is necessary 
to ensure proper storage and handling (a cold chain), as well as appropriate 
‘sharps’ training of qualified medical personnel[33, 37].  These requirements not 
only complicate the administration of such vaccines, but serve to further increase 
their cost.   
 To avoid obstacles such as cost and complicated administration, mucosal 
vaccination via the nasal and/or oral route can be utilized.  Presenting antigens to 
mucosal surfaces generally results in the production of both mucosal and 
systemic antibodies, as well as the induction of a cell-mediated immune 
response.  Together with the ease of administration available in oral or nasal 
routes, this makes mucosal immunization one of the leading vaccine 
technologies to date.  A successful case study can be seen in the oral polio 
vaccine (OPV).  While no longer used in the US due to polio eradication in North 
America, this only currently available oral vaccine is still used elsewhere to 
successfully combat poliomyelitis[3, 35]. Furthermore, the mucosal route can be 
utilized beyond the scope of traditional vaccines to administer tolerogens for the 
inhibition of allergies and autoimmune diseases[38].   
 The lack of mucosal therapies can be attributed, in part, to the difficulties 
presented in the gut mucosa once the antigen has been administered.  There is 
considerable risk of antigen inactivation by mucosal enzymes, rapid elimination 
from the host and the potential lack of contact required for antigen uptake by M 
cells, which is necessary for eliciting a protective immune response or 
tolerance[3].  Moreover, while mucosal tolerance is a mechanism utilized by the 
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human host to inhibit unnecessary responses to harmless particles in the diet 
and can thus be readily exploited, the lack of approved adjuvants makes eliciting 
a protective response in this manner more difficult.    
1.5 TRANSGENIC PLANT TECHNOLOGY 
Regardless of the mechanism of administration, vaccinations against infectious 
diseases and treatments for allergies and autoimmune disorders have been 
largely beyond the scope of individuals in developing countries.  Additionally, 
recent questions regarding the safety of avirulent and/or whole organism killed 
vaccines have led to an increase in subunit therapies, which utilize individual 
proteins known to elicit the desired immune response.  Such subunit therapies 
and vaccines rely heavily upon recombinant expression systems such as E. coli, 
yeast and mammalian cell culture for production.  New technologies in 
fermentation, purification, storage and sterile delivery have made the production 
of such vaccines and treatments more numerous but have also resulted in a 14-
fold increase in their cost in the last ten years[39]. 
 In response to these difficulties, a growing number of plant-based vaccine 
antigens and pharmaceuticals have been developed.  Transgenic plant 
technology is desirable for a number of reasons.  First, a plant expression system 
would have no risk of viral, bacterial or prion contamination, as no known human 
or animal pathogens are able to infect plants[40].  Secondly, a number of food 
crops are already utilized in the human and livestock diet, making production and 
processing of such crops for use as bioreactors extremely cost effective.  
Furthermore, transgenic plant pharmaceuticals would reduce the need for 
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maintaining a cold change during transport and storage, thus reducing the overall 
cost of production and delivery[41].  Most importantly, plant-based 
pharmaceuticals and vaccines could be administered orally, eliminating the need 
for peritoneal injection and specially trained personnel[40]. 
 A variety of plants have been utilized in the production of vaccines and 
pharmaceuticals in recent years.  Early studies used tobacco as the model 
organism and successfully produced a number of pharmaceutical proteins 
including human growth hormone and human serum albumin[42, 43].  Further 
studies demonstrated the ability of plants, including tobacco, Arabidopsis thaliana 
and Safflower,  to produce functionally active serum and secretory antibodies, 
such as IgG1, IgM, SIgA and ICAM-1[44, 45].   
 More recently, edible plants have been the focus for production of 
vaccines and therapeutics.  Tomatoes, potato tubers, lettuce and maize have 
recently been used to successfully express antigens against Hepatitis B virus, 
Rabies virus, Norwalk virus and an auto-antigen related to Diabetes[46-49].  
While expression of these proteins has, in some instances, exceeded 7% of total 
soluble protein[45] (TSP), such expression models still present difficulties.  Plants 
such as tomatoes, potatoes and lettuce have extremely high water content and, 
thus, a relatively low protein concentration.  In order to produce commercial 
amounts of the desired antigen, the biomass of the plant would have to be 
increased dramatically.  This reduces the cost-effectiveness of the plant-based 
model.  In addition, proteins expressed in leaf or fruit tissue would require freeze-
dried storage or purification for long term use.  This further reduces the 
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economical value of the system.  To restore the efficiency of the plant-based 
system, the expression platform should have a higher protein concentration, 
thereby making large-scale production of antigen much more accessible. 
1.6 SOYBEAN 
Like tobacco, maize and other crops used for protein expression, a Glycine max 
or soybean platform has little risk of contamination and is easily produced with 
processes already in use.  Unlike other crops, however, soybean has the 
additional advantage of containing approximately 40% protein, dry weight[50].  
This reduces the biomass of soybean necessary to produce commercial amounts 
of a desired protein.  Furthermore, the soybean seed is a protein storage 
vacuole, which can be housed at ambient temperatures indefinitely.  Therefore, 
any protein targeted to express in the seed could be stored for long term use 
without a cold chain or the need for flash frozen tissue materials[51].  Most 
importantly, proteins expressed at levels greater than 2% in soybean seeds can 
generate milligram amounts of protein in a single seed[52].  These seeds can 
then be further processed to produce small doses of soymilk for oral 
consumption and antigen delivery.  These factors make soybean the leading 
platform in which transgenic plant technology should be developed. 
 In addition to the efficient and cost-effective advantages presented by the 
soybean platform, the use of Agrobacterium tumefaciens horizontal gene transfer 
transformation is a naturally occurring process that requires little additional 
technology (figure 5).  The gene of interest in cloned into a binary vector, which 
can be transformed into both prokaryotic and eukaryotic hosts.  The vector is 
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then transformed into the bacterium, and the bacterium is then allowed to infect 
the soybean plant.  Using tissue culture methodology, the soybean tissue is 
grown up, and transgenic plants are identified via an herbicide resistance marker 
built into the original vector (figure 6). 
 We propose the utilization of the soybean platform for the production of 
the immunomodulatory proteins, human thyroglobulin (hTG) and merozoite 
surface protein (MSP) 119 and 142.  We hypothesize these proteins can be 
successfully expressed in soybean and used as diagnostic analytes and as oral 
therapies for tolerance and subunit vaccines. 
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Figure 1.1 
 
 
Figure 1.1: Mucosal Immunology:  Dendritic cells (DC) can capture antigen from 
the gut lumen in one of two ways: 1) DC extend ‘dendrites’ through between the 
epithelial cells and sample the gut lumen directly or 1b) antigen from the gut 
passes through microfold cells (M-cells) to cross the epithelial barrier and DC 
sample in the perifollicular area.  2) Once the DC capture the antigen, they 
present it to CD4+ T cells (via the CD40 ligand) in the perifollicular space to 
activate them.  3) Upon activation, these T cells release TGF-beta, Il-4, 5,6, 10 
and 13, which are IgA inducing cytokines leading to 5) hypermutation and 
antibody class switching in naïve B-cells, activating them to become IgA effector 
cells. 6) Activated B-cells then home to the lamina propria where they 
differentiate to high affinity plasma cells. 
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Mucosal Tolerance: Two tolerance mechanisms are currently 
elucidated. b) With high dose antigen administration, one sees the anergic 
response, the incomplete activation of the relevant T-cell. c) With lower doses of 
antigen, one observes the suppression of the response by T-regulatory cells via 
cytokine production and inhibitory receptors.   
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Figure 1.3 
 
 
 
 
 
Figure 1.3: Plasmodium life cycle: As few as 10 plasmodium sporozoites are 
injected into the host by the bite of the female Anopheles mosquito.  Within 30 
minutes to an hour, these sporozoites make their way to the liver.  Once there, 
they invade hepatocytes and mature into merozoites, a process of approximately 
two weeks.  This stage of disease is asymptomatic.  Once the merozoites 
mature, the liver cell ruptures, releasing thousands of merozoites into the 
bloodstream.  Merozoites then invade erythrocytes.  Inside the erythrocyte, they 
reproduce asexually for twelve hours, the erythrocyte bursts and the process 
begins again.  
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Figure 1.4 
 
 
 
 
Figure 1.4: Hashimoto’s thyroiditis glandular fibrosis: Thyroid disease accounts 
for more than 30% of all organ-specific autoimmunity, with Hashimoto’s thyroiditis 
(HT) being the most prevalent, affecting over 3% of the global population, 
predominantly women.  HT is the result of chronic thyrocyte depletion and, thus, 
a reduction in thyroid hormone production.  Thyrocyte depletion is caused by 
immunocyte infiltration into the thyroid parenchyma and subsequent destruction 
of the thyrocytes, ultimately leading to gland fibrosis. 
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Figure 1.5 
 
 
 
 
 
Figure 1.5: Agrobacterium transformation: Horizontal gene transfer is the 
integration to the plant genome of a specific fragment of DNA. These genes 
express proteins called Opines, a carbon source for the bacterium. This process 
is regulatedby a set of genes known as Vir genes, activated by wounded plant 
phenolic compounds (http://arabidopsis.info/students/agrobacterium/index.html). 
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Figure 1.6 
 
 
 
 
 
Figure 1.6: Soybean Transformation: A binary vector, which can be transformed 
into both eukaryotic and prokaryotic hosts, is cloned with the gene of interest.  
The vector is transformed into Agrobacterium, and the bacteria are used to infect 
plants.  It initiates horizontal gene transfer, permanently inserting pieces of its 
DNA into that of the plant.  The resulting transgenic tissue is grown up in 
selective media, producing T1 transgenic seeds. 
CHAPTER 2:  UTILIZATION OF A SOYBEAN PLATFORM FOR THE   
PRODUCTION OF THE IMMUNOMODULATORY PROTEIN, THYROGLBULIN, 
FOR USE IN DIAGNOSTIC ASSAYS 
 
 
2.1 INTRODUCTION 
Hashimoto’s thyroiditis (HT) is the primary cause of chronic autoimmune 
thyroiditis.  Affecting approximately 3% of the general population, HT is 
characterized by self-antibodies to the thyroid hormone, thyroglobulin (hTG)[25].  
Ultimately, these antibodies lead to the T-cell mediated destruction of the thyroid.   
 In addition to the thyroid destruction caused by circulating thyroglobulin 
autoantibodies, these antibodies have the potential to interfere with 
pharmacological assays which test for the recurrence of thyroid cancer.  The 
U.S. National Cancer Institute reported that over 37,000 cases of thyroid cancer 
were diagnosed in 2008, with over 1500 of these cases resulting in death.  A 
major obstacle in the early diagnosis of recurring thyroid cancer is due to the 
30% subset of thyroid cancer patients who have circulating autoantibodies to 
thyroglobulin in their sera.  These autoantibodies inhibit effectiveness of the only 
currently available assay used to test for thyroid cancer. 
 Previously, it has been demonstrated that the symptoms of HT can be 
abrogated via the oral feeding of human or porcine thyroglobulin[53, 54].   Such 
studies in combination with the ability of oral tolerance mechanisms to induce 
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systemic tolerance suggest that Hashimoto’s thyroiditis may be clinically 
diminished or eliminated via oral tolerance dosing regimens. 
 One of the primary auto antigens in HT is human thyroglobulin (hTG), a 
660kDa glycoprotein composed of two 330kDa monomers[55].  It is produced in 
the thyrocytes and  functions as a hormone storage protein, later metabolized to 
produce thyroid hormones T3 and T4[56].  hTG is heavily glycosylated and 
iodinated in vivo, which contributes to its implication as an auto-antigen in 
hypothyroid disease[57, 58].  As previously indicated, hTG is post-translationally 
modified by both glycosylation and iodination.  It has been demonstrated that 
glycosylation occurs in a step-wise fashion as the protein moves from the rough 
endoplasmic reticulum to the Golgi apparatus[59, 60].  This modification of the 
protein is necessary for proper folding and final tertiary structure.  However, it 
has been shown that iodination is not required to maintain structural integrity of 
the protein and acts as an antigen enhancer in autoimmune disease[58, 61, 62].  
Harvesting of thyroglobulin from human cadavers is the currently accepted 
method of obtaining the protein, although it presents a number of difficulties.  
This inefficient, costly source provides all the necessary thyroglobulin for medical 
assays related to thyroid cancer and autoimmune thyroid disease, as well as 
laboratory research.  The inherent genetic differences in the sources present a 
significant problem in securing homogenous thyroglobulin.  Glycosylation and 
iodination patterns vary from individual to individual depending on the maturity of 
the protein, which in turn inhibits cross talk capabilities between medical assays 
and detection methods[63].  This complication, along with the limited sourcing, 
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drastically increases the cost of testing for or obtaining human thyroglobulin.  
Despite the difficulties faced in the current means of harvesting thyroglobulin, 
due to the modifications and size of the protein, as well as the disulfide bonds 
required to maintain the dimer, it has not yet been expressed in any currently 
available recombinant protein expression system.                                                            
 In response to these difficulties, we propose that production of 
thyroglobulin in Glycine max (soybean) efficiently and cost effectively addresses 
these issues.  Soybean seeds are approximately 40% protein by dry weight, with 
the majority consisting of seed storage proteins[64].  Due to this increase in 
protein concentration, transgenic protein expression levels have been 
demonstrated to be much higher than those found in other plant systems[52, 65].  
The increase in protein expression seen in the soybean system leads to a 
number of characteristics that emphasize the cost effectiveness of the platform.  
The amount of biomass required for commercial production of pharmaceuticals is 
greatly reduced in soybean, thereby reducing the cost of greenhouse production 
and cultivation, enabling the crop to be contained.  Furthermore, production and 
harvesting processes are already in place, as soybean is an established food 
crop[66], thereby reducing the cost associated with establishing commercial 
harvesting processes  and manufacturing facilities.  In addition to high expression 
levels, soybean seeds are naturally stable at ambient temperatures.  It has also 
been demonstrated that antigens expressed in the seed remain stable and retain 
antigenicity following long term storage at ambient temperatures[67].    
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 Furthermore, early studies demonstrate the success of the soybean 
system, as shown by the expression of an approximately 200kDa monoclonal 
herpes antibody in  Zeitlin et al[68].  Later studies go further, specifically targeting 
proteins to the seed[65] and even demonstrating retention in specific sub-cellular 
compartments within the seed storage parenchyma cells[52].  These most recent 
studies have achieved expression levels greater than 2% of total soluble protein 
in the seed, thereby demonstrating commercial production a viable option from 
this system.  The success of these studies may be attributed to the favorable 
environment encountered by such proteins in the seed.  The major seed storage 
protein, Glycinin, comprises approximately 35% of total seed protein[64].  
Therefore, it is reasonable to suggest that the inherent storage capacity of the 
seed generates an environment in which proteins are easily expressed and 
retained as storage molecules.  Therefore, we conclude a storage protein, such 
as human thyroglobulin, would be successfully expressed and retained in such 
an environment, potentially providing an alternative source of protein to that of 
the currently available cadaver-based system.   
2.2 MATERIALS AND METHODS 
Vector design and construction 
The 8.3 kb human thyroglobulin gene containing a native signal peptide 
sequence, a histidine tag sequence, and 5’ and 3’ terminal restriction 
endonuclease sites was optimized for soybean codon usage and synthetically 
generated by GeneArt, Inc. (Burlingame, CA).  Following digestion with NcoI and 
XbaI, the synthetic gene was isolated from an agarose gel and ligated with 
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pTN200 that had also been linearized with NcoI plus XbaI and gel-isolated.  The 
resulting product, pTN-hTG, was verified for integrity and transformed into 
Agrobacterium.       
Soybean transformation 
Soybean transformation using the Agrobacterium-mediated half seed method 
was performed (by K. Wang in Iowa and T. Clemente in Nebraska) as described 
in Paz et al[69].  Briefly, half-seed explants (G. max cv Williams) were dissected 
and inoculated with Agrobacterium suspension culture (strain EHA101 carrying 
various binary vectors).  The inoculated explants were placed adaxial side down 
on cocultivation medium at 24°C and under 18:6 photo period for 3-5 days.  After 
cocultivation, explants were cultured for shoot induction and elongation under 
glufosinate selection (8 mg/L) for 8-12 weeks.  Herbicide resistant shoots were 
harvested, elongated and rooted as described[69].  Acclimated plantlets were 
transferred to soil and grown to maturity in the greenhouse.  Transformation 
resulted in a total of five independent transgenic events.   
Preparation of genomic DNA and PCR 
Genomic DNA was prepared from cotyledon tissue using the Maxwell 16 
Instrument and Maxwell Tissue DNA Purification Kit (Promega, Madison, WI).  
Genomic DNA (100 ng), TG primers (forward: 5’-
GCTCAACCACTTAGACCATGCGA-3’; reverse: 5’-
TCAGCGCAGTGGCAATATCCTG-3’), vsp primers (forward: 5’-
GCTTCCACACATGGGAGCAG-3’; reverse: 5’-CCTCTGTGGTCTCCAAGCAG-
3’), and dNTPs were mixed with GoTaq Flexi DNA polymerase and buffer 
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(Promega Corp., Madison, WI) according to the manufacturer’s directions.  
Following an initial denaturation cycle (5 minutes at 94°C) the reactions were 
subjected to 38 cycles of denaturation (45 seconds at 94°C), annealing (30 
seconds at 58°C) and extension (60 seconds at 72°C).  PCR products were 
visualized in 1.0% agarose gels stained with ethidium bromide.  
Glufosinate screening 
To monitor for expression of the herbicide selectable marker, plants were 
sprayed with glufosinate herbicide spray (80mg/l) a total of three times (days 1, 
3, and 5).  Plants with visible chlorosis similar to that observed in nontransgenic 
plants were scored as negative for resistance to the herbicide and discarded 
while positive plants were taken to maturity.  Plants known to be positive for 
expression of Bar were included as a control for spray concentration and 
application.   
Seed protein extraction 
Seed slivers (chips) derived from cotyledon tissue (~10 mg) were resuspended in 
150!l PBS and sonicated for 30 seconds using a Vibra-Cell ultrasonic processor 
(Newton, CT).  Samples were clarified from soluble debris by centrifugation at 
16.1 x 103g at 4ºC.  Total soluble protein was quantified with the Bradford 
Reagent (Bio-Rad, Hercules, CA) using BSA as a standard.    
Western blot analysis 
Protein extracts from transgenic and wild type seeds were run in 5% native 
polyacrylamide gels for approximately 2 hours at 110V.  Neither the gel nor the 
running buffer contained "-mercaptoethanol or SDS, and samples were not 
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boiled prior to loading onto the gel.  Human TG protein and horse spleen 
apoferritin (Sigma, St. Louis, MO) were included for standards and a 400kDa 
molecular weight marker, respectively.  Following electrophoresis, gels were 
equilibrated in 1X CAPS (recipe for 20X: 22.13g CAPS, Sigma, in 500ml dH2O, 
pH 11) buffer with 10% MeOH for 10 minutes and transferred to Immobilon-P 
membrane (Millipore, Billerica, MA).  Membranes were blocked overnight with 
5% dry milk in PBS solution at 4ºC, incubated with rabbit anti-TG polyclonal 
antibody (Gene Tex Inc., Irvine, CA) for 3 hours at 23ºC, and washed three times 
(10 minutes each) with PBS containing 0.05% Tween.  Membranes were then 
incubated with goat anti-rabbit HRP-conjugated IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 30 minutes at 23ºC and washed as described above.  
Detection was carried out using the SuperSignal West Pico substrate (Thermo 
Scientific, Rockford, IL).   
Confocal microscopy 
Whole seed tissue was imbibed for 16 hours in 1X PBS and the seed coat was 
removed.  Tissue was then fixed essentially as described previously by our 
laboratory (Oakes et al, 2009, also check the Piller Planta paper).  Sections were 
permeabilized with 1X PBS containing 0.2% Tween for 10 minutes, and then 
nonspecific binding was blocked by incubation with 1X PBS supplemented with 
3% BSA for 16 hours at 4°C.  Tissue was then incubated with rabbit anti-hTG 
serum (1:200) for 2 hours at 23ºC, followed by incubation with an AlexaFlour488 
goat anti-rabbit IgG-HRP conjugated secondary antibody (1:200) for 1 hour at 
23ºC.  Finally, tissue was incubated with DAPI stain (1:500) for 5 minutes.  Cover 
 29 
slips were added to the sections using Gel/Mount aqueous mounting media.   
Images were collected with a LSM 710 Spectral Confocor 3 Confocal Microscope 
(Carl Zeiss, Inc.) using a  20X objective and a 405nm laser to visualize DAPI 
stained nuclei, along with a 488nm laser to collect emitted fluorescence from the 
alexafluor.  Stacks of images were collected in the Z plane of the specimens. 
These stacks were comprised of 14 optical sections that were ~80nm apart.  
Resultant stacks were projected to form a single image, and this image was 
exported to Adobe Photoshop 2.0. To improve clarity and reproduction quality, 
image colors were proportionally enhanced. 
Quantification of recombinant protein in seed extracts 
Samples of human thyroid purified thyroglobulin (20, 30, 40 and 50ng) were run 
on a 5% SDS-polyacrylamide gel.  Samples were prepared in SDS-sample buffer 
without "-mercaptoethanol or boiling.  5ug of total protein extract from soy line 
77-5 were also loaded.  Western blots were performed as described above (see 
Western blot analysis).  Using ImageJ software[70], we measured the Integrated 
Density of the resulting x-ray film to compare the optical density of the known 
standard amounts against that of the soy protein sample.  The image was 
inverted and background subtracted to eliminate background pixel values.  The 
Integrated Density of each lane was measured individually, and the quantification 
of hTG in the soy protein sample was determined by the resulting standard 
curve.  
ELISA quantification was performed using the in-house sandwich ELISA as 
described below (see ELISA).  Known amounts of human thyroid purified 
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thyroglobulin were plated (0.01ng-10ng) to generate a curve and identify the 
linear range of detection.  5ug soy protein samples were loaded using a number 
of dilutions to ensure results fell within the linear range (undiluted, 1:10, 1:100 
and 1:1000).  Absorbance values were compared to those of known values to 
determine the amount of hTG present in the soy protein samples.  Considering 
dilutions, amounts were converted to percentage of hTG per sample. 
Gel filtration chromatography 
A Sephacryl S-300 HR gel filtration column (bed height 72 cm) was calibrated by 
determining the peak elution volumes (absorbance at 254 nm, BioLogic LP, BIO-
RAD, Inc.) of a set of molecular weight protein standards (Sigma, Inc.).  Crude, 
total soluble protein was then isolated from hTG-positive seeds, applied to the 
gel filtration column, and eluted fractions were collected.  Similarly, human 
thyroid-purified thyroglobulin (Calbiochem, Inc.) was applied to the same column, 
and eluted fractions were also collected.  Eluted fractions were then subjected to 
ELISA (Orgentec) to detect the presence of immunoreactive thyroglobulin in each 
fraction.   
ELISA 
Three different types of capture ELISAs were performed in this study.  The first 
two utilized commercial kits that contained either polyclonal antibody pairs 
(Orgentec Immunometric Enzyme Immunoassay kit; Orgentec, Germany) or 
monoclonal antibody pairs (Kronus META-Tg Serum Thyroglobulin assay kit; 
Kronus, Boise, ID) for capture and detection of TG.  ELISAs using both 
commercial kits were performed according to the specific manufacturer’s 
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directions.  A third sandwich ELISA was developed in house and utilized a 
monoclonal antibody for capture and a polyclonal antibody for detection.  Briefly, 
500 ng of capture antibody (GTX21984, GeneTex, Irvine, CA) was coated onto 
ELISA plates by incubation at 4°C for 16 hours.  Unbound antibody was washed 
with phosphate buffered saline (PBS) and nonspecific binding sites were blocked 
by incubation with 1% BSA in PBS for 1 hour at 23°C.  Soy protein samples and 
the bovine TG standard were then loaded onto plates and allowed to complex 
with the bound antibody for 2 hours at 23°C.  Unbound products were washed 
and a rabbit polyclonal detection antibody (GTX73492, GeneTex, Irvine, CA) was 
allowed to bind to the antigen for 2 hours at 23°C.  The secondary antibody was 
detected using a goat anti-rabbit IgG-HRP antibody (sc2004, Santa Cruz 
Biotechnology, Santa Cruz, CA) by incubation for 1 hour at 23°C.  The antibody-
antigen complexes were incubated with TMB Substrate (BioFX, Owings Mills, 
MD), and colorimetric reactions were stopped by the addition of 0.6 M sulfuric 
acid.  Absorbance values were read at 450nm.  
2.3 RESULTS 
Transformation and Molecular Screening of T1 events 
Human thyroglobulin (hTG) is an extremely large protein (330kDa) that contains 
a signal peptide and is presumably translated by the secretory pathway.  To 
maximize the likelihood that full length hTG would be stably expressed and 
accumulate within soybeans, a synthetic TG gene was designed based on the 
human amino acid sequence and optimized for high frequency codons used 
within Glycine max (Figure 2.1).  The synthetic TG gene was constructed and 
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subcloned downstream of a strong seed-specific promoter, resulting in the binary 
vector pTN-hTG (Figure 2.2a) which contains a glufosinate resistance marker 
(Bar gene) and was used for Agrobacterium-mediated transformation of soybean.  
This transformation yielded five independent T0 transgenic lines (77-3, 77-4, 77-
5, 77-7 and 77-12) that were taken to maturity in the greenhouse and allowed to 
set seed.  Parent T0 plants, as well as T1 and T2 plants in subsequent 
generations, appeared phenotypically normal to nontransgenic plants with 
respect to leaf color, growth height, and seed yield (Figure 2.2b).   
 To screen for the presence of the hTG transgene, individual T1 progeny 
from each of the five transgenic events were screened using a duplex PCR 
assay.  Slivers of cotyledon material (~20 mg) were collected from T1 seeds prior 
to germination.  Genomic DNA was prepared from ~10 mg of the harvested 
material, and mixed with primer sets that should amplify a 325 bp fragment 
internal control (soybean vegetative storage protein gene) as well as a 650 bp 
fragment diagnostic of hTG in those progeny containing the transgene.  Figure 
3a shows that T1 progeny from all five of the initial transformation lines acquired 
the hTG transgene.  In one line (line 77-3) all progeny had acquired the hTG 
transgene while in the remaining four lines some of the progeny were PCR-
negative, demonstrating that the locus or loci containing the T-DNA had 
segregated away.  Despite the fact that only six progeny from each line were 
analyzed, the presence of both TG-positive and TG-negative individuals in some 
of the lines demonstrates that the transgene is segregating.  Overall, the PCR 
results are consistent with a prior progeny screen experiment in which a different 
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subset of T1 seeds were germinated and sprayed with glufosinate to demonstrate 
herbicide resistance consistent with expression of the bar gene (data not shown).  
Based on this PCR screen, T1 progeny that were negative for the TG transgene 
were discarded while those positive for the gene were allowed to mature and set 
seed.     
 Since the presence of a transgene is not always correlated with transgene 
expression, western analysis was performed to visualize the profile of any 
transgenic protein that accumulated within T1 progeny seeds.  Total soluble 
protein was extracted in PBS from the remaining 10 mg of harvested cotyledon 
tissue, and 10!g of protein extract was separated in native polyacrylamide gels.  
Rabbit sera containing polyclonal anti-hTG antibodies were used to 
immunologically detect seed proteins with epitopes similar to those from hTG 
protein.  To serve as positive and negative controls, purified hTG protein and 
soluble protein extract derived from nontransgenic seeds were also included on 
the gels.  Figure 2.2b shows that progeny from lines 77-3, 77-5, 77-7 and 77-12 
all accumulated immunoreactive protein detected by anti-TG antibodies.  Control 
lanes containing nontransgenic seed extract or seed extract from isogenic 
samples shown to be PCR-negative for TG did not contain immunoreactive 
proteins, demonstrating the specificity of the antibodies for hTG epitopes.  In 
contrast to the four lines containing immunoreactive protein, the six T1 progeny 
derived from line 77-4 did not contain immunoreactive protein, suggesting that 
TG protein accumulation was either absent or below the level of detection in this 
assay.  It should be noted that immunoreactive protein from several of the 
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individual progeny migrated at 330kDa and 660kDa, analogous to where 
monomers and dimers of the TG standard were detected.  Thus, measurable 
amounts of proteins immunologically similar to hTG, and with a molecular weight 
consistent with that of purified hTG protein, accumulate within transgenic seeds.  
Time course studies show that the solubilized immunoreactive protein remains 
stable for at least 48 hours following extraction (data not shown). 
 Soybean-derived hTG remains intracellular 
Although the synthetic hTG gene was designed to mimic the human gene, it was 
unclear whether the soybean-derived transgenic protein would be secreted into 
the apoplastic spaces or were retained within the cell.  Immunohistochemistry 
was therefore carried out on cotyledon tissue using fluorescently-labeled hTG 
antibodies.  The images in Figure 2.4 show immunoreactive protein was not 
secreted into apoplastic spaces, but instead remained intracellular and was 
localized to the cell membrane.  Very little transgenic protein was found 
throughout the cytoplasm, and DAPI staining of nuclear material showed that 
transgenic protein was also excluded from the nucleoplasm.  No fluorescence 
was observed in nontransgenic control tissues subjected to the same conditions. 
Soybean-derived thyroglobulin protein is recognized by commercially available 
ELISAs 
To further evaluate thyroglobulin protein expression by transgenic soybean 
seeds, two different commercially available ELISAs were used.  Both of these 
ELISAs use pairs of antibodies in a capture/detection format and are frequently 
used in the diagnostic industry.  Total soluble protein was isolated from T1 
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cotyledon tissue derived from each of the five transgenic soybean lines.  These 
T1 soluble protein isolates were then assayed using a commercially available 
Orgentec ELISA kit to detect the presence of human thyroglobulin.  Soluble 
extract from nontransgenic seeds and purified human TG served as negative and 
positive controls, respectively.  Figure 2.5 demonstrates that four of the five 
transgenic lines tested exhibited seed-specific levels of immunoreactive 
thyroglobulin.  Consistent with the western results shown in Figure 2.2, progeny 
derived from line 77-4 exhibited no detectable activity.  The commercially 
available ELISA from Orgentec uses polyclonal anti-human thyroglobulin 
antibodies to capture and detect human thyroglobulin.  Such polyclonal 
antibodies likely bind both linear and conformational epitopes along the length of 
the thyroglobulin molecule.  Thus, the immunoreactivity observed in lines 77-3, 
77-5, 77-7 and 77-12 suggests that soy-derived TG epitopes are intact and that 
the protein molecule is properly folded. 
 A more stringent test to evaluate the nature of soy-derived thyroglobulin 
was the use of an ELISA procedure that utilized monoclonal antibodies for 
capture and detection.  The commercially available ELISA produced by Kronus, 
Inc. employs monoclonal antibodies that can simultaneously recognize two 
different conformational determinants on human thyroglobulin.  We used this 
assay to indicate the levels of thyroglobulin present in selected soy protein 
samples that were identified as expressing this protein in Figure 2.4.  Soluble 
extract from the highest expressing T1 progeny identified in the Orgentec ELISA 
(figure 4) was chosen for analysis in the Kronus assay, and two dilutions (10-1 
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and 10-2) of each sample extract were tested to ensure absorbance readings 
remained within the linear range (0.1-1.0) of detection.  The results from this 
Kronus ELISA experiment are shown in Figure 2.6.  As predicted, representative 
soluble extracts from each of the four lines tested contained immunoreactive 
thyroglobulin.  The fact that the Kronus ELISA uses two monoclonal antibodies to 
capture and detect thyroglobulin provides further support for the authenticity of 
soybean-derived thyroglobulin. 
Soy-derived thyroglobulin is stable over generations 
Purification of TG and potential use of this purified protein as a pharmaceutical or 
analyte is only practical if protein expression and accumulation is maintained 
over generations.  To examine whether soy-derived TG also accumulates in T2 
seeds, polyacrylamide gel electrophoresis and western analyses were performed 
using 5!g of seed extract derived from ten individual T2 seed slivers harvested 
prior to germination and T2 growth in the greenhouse.  Figure 2.7 shows that T2 
progeny from each of the four lead lines accumulated protein that reacted with 
polyclonal anti-hTG antibodies.  Furthermore, the migration pattern of 
immmunoreactive protein in several of the T2 progeny was consistent with the 
distinct 330kDa monomers and 660kDa dimers detected in the purified hTG 
standard.  This was most notable in T2 progeny derived from line 77-5 (e.g. T2 
progeny derived from 77-5 T1-2, T1-5 and T1-6 parents).  These western results 
therefore demonstrated that accumulation of soy-derived hTG is stable over at 
least two generations. Additionally, we identified several lead candidates with 
optimal expression that can be screened for zygosity and, if found to be 
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homozygous, can be bulked up for seed production, hTG protein purification and 
comprehensive protein analytical characterization. 
Partial purification of soybean-derived hTG 
To begin a physico-chemical characterization of soybean-derived thyroglobulin, 
gel filtration chromatography was used to partially purify soy-derived TG present 
in soluble protein extracts of ELISA-positive and Western-positive seeds.  A 
Sephacryl S-300 HR gel filtration column was calibrated by determining the peak 
elution volumes of a commercial set of molecular weight protein standards 
ranging in size from 669,000 MW down to 29,000 MW.  The elution volumes and 
molecular weights of the protein standards are indicated on the chromatogram 
plot in Figure 2.7a.  It should be noted that the peak bovine TG standard (MW 
669,000) eluted in fraction #20.  After the gel filtration column was washed, 
soluble protein extract from lines 77-7 #6 and 77-3 #6 was applied to the column 
and eluted fractions were collected.  Protein absorbance (280 nm) was recorded 
during elution and fraction collection and plotted as relative absorbance.  The 
bulk of native soluble seed proteins eluted from the gel filtration column in 
fractions 16-19.   
 The eluted fractions were subjected to a sandwich ELISA that was 
previously developed in-house to detect the presence of immunoreactive TG.  
The sandwich ELISA utilized a monoclonal capture antibody and a polyclonal 
detection antibody.  Figure 2.8b shows the immunoreactive profile for soybean-
derived TG infractions 11-34, plotted as relative absorbance at 450 nm.  
Although fractions 16-24 all contained detectable levels of immunoreactive TG, 
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the majority of the immunoreactivity was detected in fractions 19-21.  Notably, 
the bovine TG standard (669,000 MW) was previously shown to elute in fraction 
20 (Figure 8a).  Therefore, the ELISA results strongly suggests that soybean-
derived TG folds in a manner similar to that of the commercial bovine TG 
standard and can exist as a ~660kDa dimer.     
 For a comparison, human thyroid-purified TG was also run over a 
Sephacryl column, and analogous fractions were collected and assayed for 
immunoreactivity using the ELISA described above.  The immunoreactive profile 
for hTG was also plotted as relative absorbance and is shown in Figure 2.8a.  In 
contrast to the tight peak of immunoreactivity observed in the soy-derived TG 
profile (fractions 19-21), the peak activity of thyroid-purified hTG was spread over 
fractions 16-27.  This result suggested that commercial hTG may not be as 
homogenous as soybean-derived TG.   
 To analyze whether soy-derived TG dimers were present in eluted 
fractions, western analyses were performed.  Equivalent volumes of fractionated 
sample from eluted fractions containing soy-derived TG and thyroid-purified TG 
were separated in native polyacrylamide gels, and immunoreactive proteins were 
detected using polyclonal anti-hTG antibodies.  To serve as a visual marker, hTG 
was included as a standard in each experiment.  Figure 8b shows that eluted 
fractions containing peak ELISA immunoreactivity also contained the greatest 
level of signal in the western experiments.  Furthermore, the migration of 
immunoreactive protein in soy-derived TG eluted fractions was analogous to that 
of the 660kDa hTG dimers observed in the standard.  These results further 
 39 
demonstrate that native soy-derived TG is capable of forming functional dimers.  
Consistent with the profiles in Figure 2.8a, the greatest levels of soybean-derived 
TG signal were detected in fractions 19-21 while the greatest levels of thyroid-
purified TG were spread over fractions 17-23.  These results suggested a 
potential difference in the homogeneity of the human sample compared with that 
of the soy-derived sample. 
2.4 DISCUSSION 
To date, the sole source of purified hTG for use as a research and diagnostic 
reagent is derived from human cadaver and surgically removed thyroid tissue.  In 
this study we have successfully expressed a recombinant form of hTG in 
soybean seeds.  The expression of hTG in soybeans represents one of the 
largest recombinant proteins expressed in any plant host system to date and 
creates an alternate and novel source for this relevant protein.  The authenticity 
of recombinant hTG was confirmed by ELISA using commercially-available kits 
developed specifically for the detection of hTG (Figures 2.5,2.6).  Western 
analyses and gel filtration chromatography experiments demonstrated that soy-
derived hTG and thyroid-purified hTG are biologically similar with respect to size, 
charge, mass and subunit interaction (Figures 2.3, 2.7, 2.8).  The expression of 
hTG in transgenic seed extracts was stable over two generations, and 
represented ~0.8% of total soluble seed protein (Figure 2.7).                                                                                                                                                             
 To our knowledge, no literature has reported the recombinant expression 
of hTG in any host system traditionally used for the production of recombinant 
proteins.  It is not clear whether attempts to express recombinant forms of this 
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protein were unsuccessful or such attempts were never made.  However, given 
the importance of hTG in the diagnostics industry, along with the absence of an 
accepted universal standard and the issues associated with purifying 
thyroglobulin from human tissue, it seems unlikely that attempts were never 
made using traditional systems such as yeast, insect cell culture and mammalian 
cell culture.  We have demonstrated that soybeans represent a practical 
alternative to existing recombinant host systems for the expression of an 
extremely large and complex protein.  We believe that recombinant expression of 
hTG in soybeans was possible due to the fact that soybean seeds contain a 
biochemically unique environment, serving as a “sink” for the accumulation and 
storage of large protein complexes.  This is evident by the abundance of 7S and 
11S protein complexes that comprise ~70% of total soybean seed protein [64, 
71].  While the individual protein subunits that comprise the 7S and 11S 
complexes are not considered large, the mature complexes that subunit proteins 
form are indeed large in size and mass, very comparable to the size and mass of 
mature hTG.  Thus, it was conceptually logical to assume that an environment 
that has evolved to store large protein complexes would therefore represent an 
ideal target site for the expression and accumulation of a recombinant protein 
which may otherwise be difficult or impossible to express in traditional host 
systems.   
 The accumulation of recombinant hTG in line 77-5 was shown to 
represent ~0.8% of total soluble protein as measured by western densitometry 
and ELISA.  Although there have been relatively few published reports of 
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proteins targeted to soybean seeds, the observed accumulation level of seed-
specific hTG is comparable to levels of recombinant proteins reported by other 
colleagues.  For example, Ding et al [65] reported that recombinant basic 
fibroblast growth factor (bFGF) represented ~2.3% of total soluble soybean seed 
protein, while Moravec et al [52] reported that recombinant B subunit pentamers 
of E. coli heat labile toxin (LT-B) represented ~2.4% of total soluble soybean 
seed protein.  Although the expression level of hTG is not as great as that of 
bFGF and LT-B in the soy system, it nonetheless represents a significant yield of 
recombinant protein.  For example, with an expression level of 1.0%, a single 
transgenic soybean seed will contain approximately 0.6 mg of recombinant hTG 
(~180 mg seed weight x ~38% protein content x ~1.0% expression level), or 
about 150 mgs of transgenic protein per plant.  It has been suggested that 
increased levels of transgenic protein can be obtained by targeting the protein to 
the ER by inclusion of an ER retention signal (H/KDEL).  Given that optimal 
locations for subcellular expression are usually identified by trial and error, we 
have generated constructs to evaluate whether or not recombinant hTG targeted 
to the ER lumen can accumulate to levels >1% of total seed protein.  However, 
given that hTG is a secreted protein, along with the fact that misfolded hTG 
protein complexes are degraded in vivo within the ER lumen of human thyrocytes 
[72], we chose not to include the ER retention signal in our original construct 
design.                                                                                                                
 During the course of these studies, we have found that recombinant hTG 
is stable in seed extracts for at least 1 week, and stable in seeds stored for > I 
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year at ambient temperatures in the laboratory. The stability of recombinant 
proteins in soybean seeds is not surprising given that the primary purpose of the 
seed is to store proteins for long periods of time under conditions that may not be 
optimal.  Studies with other recombinant proteins targeted to soybeans have also 
demonstrated stability of transgenic proteins when seeds were stored for up to 4 
years under ambient conditions [52, 67].                                                                                              
 Stability, along with the production of a uniform product, will increase the 
means by which this alternative thyroglobulin source can be utilized.  
Commercially purified hTG is derived from human tissue and therefore 
represents a heterogeneous population comprised of immature and mature forms 
of hTG.  Immature forms of hTG lack carbohydrates and iodine residues while 
mature forms contain up to 10% carbohydrate and 1% iodine [72]. Thus, different 
batches of commercially-purified hTG can be quite dissimilar with respect to 
purity and composition.  This fact was borne out in Figure 2.7 where hTG purified 
from human thyroid tissue eluted as a relatively broad peak on molecular sizing 
chromatography columns.  We speculate that soybean-derived hTG will be much 
more homogenous than thyroid-purified hTG.  Since soybeans do not have 
enzymes for iodination, soy-derived hTG will not be iodinated.  A non-iodinated 
soy-derived hTG standard represent a significant advantage to current thryroid-
derived hTG standards since iodination increases the antigenicity of the protein, 
thereby introducing the possibility of false and/or inconsistent test results when 
used in ELISA-based screens[73, 74]  Similarly, seed proteins are stored as 
“mature” forms of protein, thus it is likely that soy-derived hTG will be uniformly 
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glycosylated.  While protein glycosylation in soybean differs from that in humans, 
the antibodies used in FDA-approved ELISAs utilizing hTG as a reference 
standard recognize the protein backbone, not the carbohydrate residues [75].  
We are currently conducting protein analytical experiments to characterize the 
extent and composition of carbohydrate modification on soybean-derived hTG.  
We anticipate that the lack of iodination, along with uniform glycosylation of 
proteins within the seed will contribute significantly to overall hTG protein 
homogeneity.                                                                                                               
 While future studies will focus on purification and analytical 
characterization of soy-derived hTG, it will also be important to characterize the 
recognition of the soybean derived protein by antibodies found in human sera, 
particularly from individuals with autoimmune hypothyroid disease.  The 
confirmation of soy-derived hTG as a bioequivalent to hTG purified from 
homogenates of human tissue will result in the first alternative sourcing of this 
protein.  It is unclear what other uses may be derived from this never before 
available resource, but possibilities include the production of novel medical 
assays and devices to improve detection and/or treatment of thyroid cancer and 
disease.  Furthermore, this resource could drastically improve the basic research 
relating to thyroid dysfunction and disease due to the increased supply and 
reduced cost of the recombinant molecule. 
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Figure 2.1 
 
Figure 2.1: hTG gene sequence. hTG sequence optimized for soybean codon 
usage and cloned into the binary vector, pTN-200, for transformation into 
Agrobacterium and Glycine max.   
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Figure 2.2 
 
 
Figure 2.2:  Gene design and soybean transformation.  A. Binary vector pPTN-
hTG used for Agrobacterium-mediated transformation.  P-7S, soybean !-
conglycinin promoter; TEV, tobacco etch virus translational enhancer element; 
hTG, synthetic human thyroglobulin gene; T-35S, cauliflower mosaic virus 
terminator element; P-nos, nopaline synthase promoter, Bar, phosphinothricin 
acetyltransferase gene for plant selection; T-nos, nopaline synthase terminator 
element; RB, right border sequence; LB, left border sequence; aad A region, 
streptomycin resistence gene for bacterial selection.  B. 60-day old transgenic 
(line 77-5) and WT (control) plants. 
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Figure 2.3 
 
 
Figure 2.3:  Molecular characterization of six individual T1 progeny derived from 
each parent line. Top panels: Agarose gel (1%) showing results from duplex PCR 
used to detect vegetative storage protein (vsp, internal control) and hTG 
sequences in genomic DNA isolated from T1 seed chips.  Amplified PCR 
products diagnostic of vsp and hTG migrate at 325 bp and 659 bp, respectively. 
Genomic DNA from control reactions are designated “WT” (wild type, 
nontransgenic) and “+” (plasmid pPTN-hTG).  The designations for molecular 
weight markers are shown in base pairs. Bottom panels: Western analysis of T1 
crude seed proteins separated in 5% native polyacrylamide gels.  The migration 
of 250 kDa and 400 kDa proteins used as visual standards is shown.  Arrows 
represent the locations of monomeric (M) and dimeric (D) forms of hTG as 
visualized in western blots by inclusion of an hTG standard (75 ng of 
commercially-purified hTG) run on each gel. 
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Figure 2.4 
 
 
Figure 2.4:  Representative confocal image demonstrating hTG accumulation in 
transgenic T1 cotyledon tissue.  The blue color represents DAPI staining while 
the red color represents fluorescence from the AlexaFluor antibody recognizing 
transgenic hTG.   
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Figure 2.5 
 
 
 
Figure 2.5:  Orgentec ELISA used for detection of hTG in six T1 progeny seed 
extracts derived from each T0 transgenic parent.  Soluble protein from 
nontransgenic seed (WT) and commercially-purified hTG (human) were used as 
negative and positive controls, respectively.  Values shown are the absorbances 
(450 nm) from six individual T1 progeny from each of the five transgenic lines, as 
well as controls.  Samples denoted with an asterisk represent the individual 
sample chosen from each line for hTG detection using the Kronus assay (see 
Figure 5). 
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Figure 2.6 
 
 
 
 
Figure 2.6:  Kronus ELISA used for detection of hTG in select T1 seed extracts, 
which had been normalized for TSP via Bradford assay.  Crude seed extract from 
one representative T1 progeny (indicated by an asterisk in Figure 4) was 
examined, along with soluble protein from a nontransgenic seed (WT) and 
commercially-purified hTG.  Five different dilutions of each selected sample were 
tested in the ELISA and absorbance values for two of these dilutions (1:100 and 
1:1000) are shown along with controls for comparison.    
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Figure 2.7 
 
Figure 2.7:  Western analysis of T2 seed protein.  A. Crude seed extracts (5 !g) 
from 10 random T2 progeny were separated in 5% native polyacrylamide gels 
and screened by western blot analysis for the presence hTG.  Thyroid-purified 
hTG (75 ng) served as a standard to visualize monomeric and dimeric forms of 
the protein.  Nontransgenic seed protein (5 !g) served as a negative control.  
The locations of 400 kDa and 250 kDa molecular mass standards, as well as the 
monomeric (M) and dimeric (D) forms of hTG are indicated.  B. Western 
quantification of recombinant hTG.  The indicated amounts of commercially 
purified hTG protein and seed extract protein (line 77-5) were incubated in SDS-
sample buffer (in the absence of !-mercaptoethanol and boiling) to relax dimeric 
protein and result in predominantly monomeric protein for visualization and 
quantification following western analysis.  A densitometry curve was generated 
by scanning the gel image and plotting integrated density of each known 
standard using ImageJ software.  Extrapolation from this curve revealed 27.97 ng 
of hTG protein in 5 ug of seed extract, representing ~0.8% of total soluble seed 
protein. (STD = Standard, TSP = total soluble protein) 
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Figure 2.8 
 
 
Figure 2.8:  Fractionation and partial purification soy-derived hTG from crude 
seed extracts.  A calibrated Sephacryl S-300 HR column was used to separate 
either a crude extract of seed protein or human thyroid purified thyroglobulin.  A. 
Eluted fractions were subjected to a capture ELISA for detection of hTG.  The 
ELISA results are shown as a percentage of the relative abosorbance (450 nm) 
for eluted fractions containing crude soybean seed protein (solid line) and human 
thyroid-purified protein (dashed line).  Fractions 1-11 and 28-36 showed minimal 
absorbance and therefore are not included on the plot.  The locations of 
molecular mass standards used for calibration are shown by arrows (669 kDa, 
bovine thyroglobulin; 443 kDa, !-amylase; 200 kDa, alcohol dehydrogenase).  B. 
Western analysis of eluted fractions.  Equal amounts of protein from the indicated 
fractions were separated in 5% native gels and subjected to western analysis.  
The location of the dimeric (D) form of hTG is indicated.                 
CHAPTER 3: ORAL ADMINISTRATION OF THE SOYBEAN-DERIVED 
IMMUNOMODULATORY PROTEIN hTG INDUCES TOLERANCE IN THE 
MURINE MODEL OF AUTOIMMUNE THYROIDITIS 
 
 
3.1 INTRODUCTION: 
Tolerance is the systemic and/or localized prevention of potentially harmful 
immune responses to a particular antigen.  Most notably, this response is seen in 
the prevention of immune responses to self antigens, molecules necessary for 
various functions but able, if unchecked, to induce a robust and unnecessary 
immune response.  Oral tolerance is generally described as the suppression of 
primarily the Th1 immune response to a specific antigen due to prior 
administration of that antigen via the oral route [15].  To date, two tolerance 
mechanisms of action have been described:  active suppression via T-regulatory 
cells (Tregs) and induction of clonal anergy/deletion[14, 15, 38].  Studies have 
suggested that low doses of oral antigen favor cell-driven tolerance, while higher 
doses of antigen induce clonal deletion or anergy of antigen specific T-cells [38, 
76, 77].   
 Tregs are a subpopulation of CD4+ T-cells and are required for the 
maintenance of self tolerance and the prevention of autoimmune disease [78].  
Such cells secrete cytokines such as TGF-!, IL-10 and IL-4 to down-modulate or 
suppress the generation and activity of effector T-cells [14, 38].  In addition to cell 
contact upon recognition of a particular antigen, adaptive Tregs have the ability 
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to induce bystander suppression, a non-antigen specific form of tolerance.  The 
cytokines produced by the antigen-specific Tregs can cross-prime CD4+ and 
CD8+ T cells in the area to induce the regulatory/suppressive phenotype in those 
cells[15].  The generation of antigen-specific Tregs seems to occur in the gut-
associated lymphoid tissue (GALT), with migration to peripheral lymphoid 
tissue[79].  As with mucosal immunity, antigen is taken up from the intestinal 
milieu by microfold or M-cells and transported to the Peyer’s Patches.  Antigen is 
presented via gut-associated antigen presenting cells (APCs) to T-cells found in 
the GALT and the mesenteric lymph nodes (MLN).  Retinoic acid from dendritic 
cells in both the GALT and MLN enhances the expression of the Foxp3 
phenotype in T-cells, resulting in Treg generation.  These Tregs can then migrate 
to the peripheral lymphoid tissues upon antigen recognition to induce systemic 
tolerance[14].   
 Clonal deletion functions via the apoptotic elimination of antigen-specific 
T-cells[35].  Studies suggest that feeding high doses of a particular antigen 
increases the susceptibility of antigen-specific T cells to undergo apoptosis 
following systemic challenge with the same antigen[80].  Gut-associated APCs 
then engulf the apoptotic cells and secrete the suppressive cytokine TGF-!, 
demonstrating that the mechanisms of tolerance most likely overlap[15].   
 Clonal anergy is the lack of function in antigen specific T cells when 
regulatory mechanisms are not present[15].  The role of anergic T-cells is best 
understood in peripheral tolerance to self-antigens[81].  However, as these cells 
have been shown to retain cytokine production capabilities and demonstrate 
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suppressive activity, it is clear they maintain a role in oral tolerance[14, 15, 38, 
81].   
 Organ-specific autoimmunity (the failure of self tolerance) is characterized 
by chronic T-cell or antibody targeting of a particular organ.  Thyroid disease 
accounts for more than 30% of all organ-specific autoimmunity, with Hashimoto’s 
thyroiditis (HT) being the most prevalent, affecting over 3% of the global 
population, predominantly women[25].  HT is the result of chronic thyrocyte 
depletion and, thus, a reduction in thyroid hormone production.  Thyrocyte 
depletion is caused by immunocyte infiltration into the thyroid parenchyma and 
subsequent destruction of the thyrocytes, ultimately leading to gland fibrosis[25, 
65, 82].  While the presence of autoantibodies to thyroid hormones such as 
thyroglobulin and thyroid peroxidase is the diagnostic hallmark of disease and 
mechanisms including cytotoxic T-lymphocyte destruction and death receptor 
induced apoptosis have been proposed, it is much more likely that disease 
pathology is a result of the interplay between these factors[28].   
 As stated previously, T-regulatory cells suppress the activity of effector T-
cells, thus inhibiting the pro-inflammatory Th1 immune response.  The Treg 
population found in the thyroid is abundant, in both healthy individuals and those 
in the early stages of autoimmune thyroid disease (AITD)[83].  Both thyrocytes 
and resident Tregs are known to express death receptors and death receptor 
ligands, such as Fas and Fas-ligand.  When induced, these molecules induce an 
apoptotic pathway, leading to the destruction of the cell[84].  Under normal 
physiological conditions, these receptors and ligands are not expressed at a 
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sufficient level in the thyroid to induce apoptosis of either the Tregs or the 
thyrocytes.  However, T-lymphocytes infiltrating the thyroid under disease 
conditions demonstrate significantly increased expression of Fas and Fas-ligand.  
This upregulation of expression together with the pro-inflammatory cytokines 
produced by the infiltrating T-cells (Il-1!, IFN-", TNF-#) result in the induction of 
the apoptotic pathway in both thyrocytes and T-regulatory cells[84-86].  The 
decrease in resident Tregs in the thyroid leads to an increase in the Th1 immune 
response that Tregs typically suppress.  This mechanism is particularly efficient 
as it exacerbates a positive feedback loop:  as more pro-inflammatory cytokines 
are released in the Th1 response, T-regulatory cells will continue to diminish via 
apoptosis, prolonging the Th1 response, enhancing cytotoxic T-lymphocyte 
activity against thyrocytes and resulting in the chronic gland fibrosis characteristic 
of disease[28].  Additionally, the lack of Tregs decreases the expression of B-cell 
inhibitory markers, such as CD25, Foxp3 and TGF-![87].  The increase in B-cell 
activity ultimately leads to production of autoantibodies against thyroid hormones 
and the activation of the complement cascade, culminating in the further 
reduction of thyroid hormones and glandular destruction. 
 Previously, we have demonstrated the successful expression of 
recombinant human thyroglobulin in the Glycine max, or soybean, platform.  As 
thyroglobulin is one of the primary antigens in HT[73], it is reasonable to suggest 
that the induction of tolerance against this antigen could have inhibitory effects to 
early onset disease symptoms and progression.  Based upon the limited success 
of previous studies[88] and the understanding of the mechanisms described 
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above, we anticipate tolerance to thyroglobulin can be achieved and HT inhibited 
prophylactically via the repeated oral administration of soybean-derived human 
thyroglobulin.   
3.2 MATERIALS AND METHODS: 
Preparation of soymilk extracts 
A total of 40 seeds from either hTG line 77-5 or wild type plants were ground to a 
fine powder.  For each gavage, 346mg of seed powder was resuspended in 3ml 
of phosphate buffered saline (PBS) and sonicated for 1 minute using a Vibra-Cell 
ultrasonic processor (Newton, CT).  Samples were spun at 15,000 rpm for 5 
minutes, and supernatant was transferred to a 1.5ml eppendorf tube.  Tubes 
were spun for an additional 30 seconds at 16.1 x 103g for clarification.   
Oral gavage of soymilk and I.P. immunization 
Six to eight week old female Balb/c mice were gavaged every other day for 26 
days as follows:  using a 22 gauge feeding needle, 200ul of either hTG soymilk 
protein extract containing 280ug hTG or wild type soymilk protein extract was 
administered to each animal via oral gavage.  On day 14, both groups were 
immunized intraperitoneally with 100ug of commercial human thyroglobulin 
(Calbiochem, UK) in aluminum hydroxide gel as an adjuvant (Sigma-Aldrich, St 
Louis, MO). 
Sera collection and tissue culture 
Following euthanasia on day 42, sera and splenocytes were isolated for 
quantification of antibody titers and T-cell restimulation assays.  Spleens were 
ground through 30 mesh screens to isolate leukocytes.  Resulting cells were 
cultured in RPMI-1640 with 20% FBS (BD Biosciences, Chicago, IL).  Cells were 
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plated at 106  cells per well in 96-well flat bottom tissue culture plates, coated with 
10ug commercial hTG or FBS and incubated for 72 hours. 
T-cell restimulation and IFN-! / IL-4 capture ELISA 
Supernatants from cultured cells were taken after 72 hours.  Supernatants were 
tested for IFN-" and IL-4 via capture ELISA.  Briefly, plates were coated with 
5ug/ml capture antibody in 0.1M NaHCO3 and incubated at 4ºC overnight.  Plates 
were washed with PBS and blocked for 1 hour with 1% BSA-PBS.  Plates were 
washed a second time, and 100ul of samples at varying dilutions were added to 
wells and incubated at room temperature for 2 hours.  Following a third wash, 
100ul of polyclonal rabbit antibody was added to each well.  Plates were 
incubated for 2 hours.  After washing with PBS, a polyclonal anti-rabbit-Ig-HRP 
conjugated antibody was added to each well and incubated for 45 minutes.  
Plates were washed and coated with TMB Substrate, with colorimetric reactions 
stopped by the addition of 0.6M sulfuric acid.  Absorbance was read at 450nm. 
ELISA determination of hTG antibody titers 
ELISA plate was coated with 100ng of commercial hTG (Calbiochem) overnight 
at 4°C.  Plate was then washed with PBS and blocked with 1% BSA-PBS for 1 
hour.  After a second wash, 100ul of sera samples of varying dilutions were 
loaded on to the plate and incubated at room temperature for 2 hours.  Following 
a third PBS wash, 100ul of anti-mouse IgG-HRP antibody (Southern Biotech) at 
1:500 dilution was added to each well and allowed to incubate for 1 hour.  The 
antibody-antigen complexes were coated with TMB Substrate (BioFX, Owings 
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Mills, MD), and colorimetric reactions were stopped by the addition of 0.6 M 
sulfuric acid.  Absorbance values were read at 450nm.  
3.3 RESULTS: 
Oral delivery of soybean-derived hTG results in lower antibody titers to 
thyroglobulin. 
Sera collected from the wild type mouse group and the soy-derived hTG mouse 
group was used to determine antibody titers against commercial human 
thyroglobulin.  To determine if there was a difference in antibody production 
between the groups, an ELISA was performed.  Figure 3.1 demonstrates that, at 
three different dilutions, there is a difference in antibody titers between the wild 
type and the hTG group.  While no statistically significant data was established, 
the individual data suggests 40% of the hTG group were tolerized.  This suggests 
the mice that received the hTG soymilk formulation induced, at least partially, 
either a high or low-dose tolerance response to the antigen in the milk, while the 
wild type mice, having never received hTG prior to peritoneal immunization, were 
unable to do so at all. 
T-cells from orally tolerized mice exhibit decreased response to thyroglobulin 
stimulation. 
To further elucidate the type of tolerance response driven by the oral 
administration of soy-derived thyroglobulin, leukocytes isolated from spleens 
were subjected to restimulation with commercial hTG.  The supernatants from 
these cell cultures were analyzed for IFN-" and Il-4 production via ELISA.  IFN-" 
is a pro-inflammatory Th1 cytokine produced by activated T-cells.  Figure 3.2 
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indicates the difference (p=0.02) in IFN-" production between T-cells from the 
wild type group and those from the hTG group.  The decreased production of 
IFN-" indicates a shift to an anergic response by the T-cells to the stimulus.  This 
is further supported by the high doses of tolerogen (280ug) administered in each 
gavage.  Furthermore, figure 3.3 exhibits no difference in IL-4 production 
between the groups.  IL-4 is a Th1 suppressive cytokine produced during a T-
regulatory cell response.  The lack of difference between the groups indicates 
that active suppression by Tregs does not play a significant role in the induction 
of tolerance against human thyroglobulin. 
3.4 DISCUSSION: 
Currently, the only available therapy for individuals with HT is lifelong treatment 
via levothyroxine, a synthetic hormone replacement.  In these studies, we 
propose a potential one time prophylactic alternative.  In the course of 28 days, 
we were successfully able to inhibit antibody production to thyroglobulin, a 
primary HT antigen, in mice, as indicated by figure 3.1.  While the response was 
not completely abrogated, we maintain that continued therapy would further 
decrease the immune response, ultimately inhibiting it completely.  This is 
supported by the data from the antibody titers, indicating that only mice who 
received hTG soybean formulations had decreased titers, while the control 
groups were entirely unaffected by the procedure.  We propose such therapy 
would be most advantageous when used prior to disease diagnosis in the target 
population:  briefly, women over 30 with a familial history of autoimmune disease.  
Furthermore, as HT is a progressive disease, such therapy could be utilized 
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during the early stages of symptom onset to inhibit further progression of disease 
pathology.   
 While the symptoms and diagnostic hallmarks, such as hTG antibody 
production, of HT are well characterized, the mechanism of disease is less so.  
Therefore, it is essential to determine the role of T-cells, as well as B-cell 
antibodies, in disease onset.  Exploring the means by which tolerance induction 
inhibits CD4+ T-cell stimulation will shed greater understanding on the 
mechanistic failures in the immune response that serve to initiate this disease.   
 As indicated previously, there are two mechanisms of tolerance induction: 
T-regulatory cell activation and clonal anergy/deletion.  During these 
experiments, we used a T-cell restimulation assay to determine the mechanism 
of tolerance being utilized in response to oral antigen delivery.  A follow-up 
ELISA for IFN-" (figure 3.2) demonstrates a pronounced difference in the 
cytokine production between the wild type and experimental groups.  As IFN-" is 
a Th1 cytokine and shows a decrease in production by experimental group (hTG) 
T-cells, it can be inferred that these cells are not responding enthusiastically to 
the thyroglobulin antigen and are, thus, exhibiting an anergic state.  Alternatively, 
the high levels of IFN-" produced by wild type T-cells indicate a robust immune 
response to thyroglobulin.   
 While IFN-" is an indicator of T-cell activity, other cytokines, such as IL-4, 
can be used to determine the response of Tregs (figure 3.3).  IL-4 is a 
suppressive cytokine secreted by Tregs upon activation.  We demonstrate no 
difference between the two groups considering IL-4 production.  Therefore, we 
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conclude that Tregs do not perform a major function in the suppression of CD4+ 
T-cell activity during tolerance induction to thyroglobulin.  This cytokine data 
indicates a follow-up experiment that should be conducted to further support our 
conclusions.  If IFN-! is suppressed as our data indicates, then the corresponding 
antibody isotype, IgG1, should also be suppressed.  In addition, as we saw no 
difference in the production of the Th2 cytokine, IL-4, the levels of the antibody 
isotype IgG2 should likewise be unchanged.  A study of this nature will serve to 
further elucidate the mechanism of action generated in response to the high 
doses of antigen we utilized. 
 Although cytokine indicators point to clonal anergy as the mechanism for 
tolerance in HT disease pathology, it should be recalled that Tregs are eliminated 
by apoptosis during HT disease progression[84, 86].  Further studies should 
focus on the re-establishment of the Treg population in the thyroid following initial 
tolerance induction to determine the actual role of these cells.  Additionally, 
studies should extend tolerance therapy to determine if complete abrogation of 
the immune response is, in fact, possible and if a pronounced difference in 
thyroid hormones T3 and T4 can be detected.  Lastly, thyroid pathology analysis 
should be conducted with and without treatment in an attempt to visualize the 
degradation, or lack thereof, inflicted by disease progression.  If these 
experiments prove successful, the cost-effectiveness of soybean-derived oral 
toleragens would radically alter the pharmaceutical approach to treating 
Hashimoto’s thyroiditis. 
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Figure 3.1 
 
 
 
 
Figure 3.1:  hTG ELISA of mouse sera to determine antibody titers.  Dilutions of 
mouse sera from wild type (WT) and thyroglobulin (hTG) groups were analyzed.  
Eight serial dilutions of each sample were tested in the ELISA and absorbance 
values for three of these dilutions are shown.  WT and hTG groups were both 
N=5.  One way analysis of variance (ANOVA) indicated no statistical significance.   
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Figure 3.2 
 
 
 
 
 
 
Figure 3.2: IFN-" ELISA used to determine T-cell restimulation in the presence of 
commercial thyroglobulin.  Splenocytes from wild type (WT) and thyroglobulin 
(hTG) groups were restimulated using commercial thyroglobulin (TG) and Fetal 
Bovine Serum (FBS) as a control.  Supernatants were collected and analyzed via 
ELISA for the presence of IFN-".  Results are shown in pg/ml.  Both groups are 
N=5.  One way analysis of variance (ANOVA) indicates a statistically significant 
difference between IFN-" production in wild type splenocytes as compared to 
thyroglobulin group splenocytes (p=0.01).   
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Figure 3.3 
 
 
 
 
 
 
Figure 3.3: IL-4 ELISA used to determine T-cell restimulation in the presence of 
commercial thyroglobulin.  Splenocytes from wild type (WT) and thyroglobulin 
(hTG) groups were restimulated using commercial thyroglobulin (TG) and Fetal 
Bovine Serum (FBS) as a control.  Supernatants were collected and analyzed via 
ELISA for the presence of IL-4.  Results are shown in pg/ml.  Both groups are 
N=5.  One way analysis of variance (ANOVA) indicates no significant difference 
between IL-4 production in wild type splenocytes as compared to thyroglobulin 
group splenocytes. 
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CHAPTER 4:  PRODUCTION OF SOY-DERIVED MALARIAL ANTIGENS 
MSP119, MSP 4/5 AND MSP 142 FOR ORAL IMMUNIZATION IN THE MURINE 
MODEL 
 
 
4.1 INTRODUCTION 
As one of the world’s major diseases, the Plasmodium species that cause 
malaria are responsible for the deaths of approximately 5 million people each 
year, with the majority of those being under 5 years of age.  Largely endemic in 
sub-Saharan Africa and Asia, malaria is a disease of the vulnerable and 
impoverished populations found in developing countries.  Transmitted via the bite 
of the female Anopheles mosquito, infection at some point during one’s life span 
in these areas is all but guaranteed.   
 Following initial infection, there are two parts to the immune response.  
The first focuses around the pre-erythrocytic or live stage of infection, dependent 
upon CD8+ T-cells and a pro-inflammatory Th1 cytokine response.  Upon 30 
minutes of inoculation, as few as 10 malaria sporozoites make their way to the 
liver and invade host hepatocytes.  The speed with which this happens renders 
an anti-sporozoite antibody response useless, as antibodies are generally not 
present in the circulation at high titers when infection occurs[89].  An attempt to 
clear liver stage infection is dependent upon T-cell activity, for which there are 
two potential mechanisms of action.  The elimination of hepatocytes infected with 
Plasmodium could be achieved via the classical CD8+ cytotoxic T-lymphocyte 
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(CTL) activity:  perforin/granzye-mediated apoptosis[90].    Additionally, CD4+ 
CTLs respond to infected hepatocytes in a similar manner, forming an 
immunological synapse upon contact and inducing apoptosis[91].  These cells 
are most efficient upon re-infection, activated in response to circumsporozoite 
protein (CSP), released by Plasmodium upon hepatocyte invasion[92].   
 Alternatively, non-cytotoxic CD8+ and CD4+ T-cells could eliminate 
sporozoites via their interaction with antigen presenting cells (APCs) in the liver, 
the production of IFN-!  and the induction of the nitric oxide (NO) pathway[89, 90, 
93].  T-cells specific for CSP presented by infected hepatocytes via MHC class I 
in the liver produce large amounts of IFN-!, which in turn induces the nitric oxide 
pathway in the hepatocytes, thereby killing the Plasmodium parasites within.  As 
high concentrations of IFN-! and NO are routinely found in individuals with 
naturally acquired immunity, it is likely this cytokine/NO pathway is the means by 
which malarial infection is arrested in the liver[93, 94].   
 The second part of the immune response focuses on blood stage 
infection, in which mature merozoites are released from the liver into the 
bloodstream to infect red blood cells (RBCs) and induce disease pathology.  The 
hallmark of blood stage malaria is a severe fever with chills, cycling 
approximately every 12 hours.  This stage of infection leads to RBC adherence to 
vascular walls, severe anemia and, ultimately, death.  As thousands of 
merozoites are released into the bloodstream to infect RBCs, the immune 
response at this stage is generally over-enthusiastic, likening the infection to 
sepsis, in which the immune response does a large portion of the damage[93].  
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During the erythrocytic stage, the immune response is mediated largely by the 
humoral response:  the activation of B-cells and the production of antibodies.  
The role of antibodies is multifaceted, as they serve to block RBC invasion, 
induce antibody-dependent cellular cytotoxicity (ADCC), activate T-cells and 
opsonize infected RBCs for the induction of the classical complement 
pathway[93, 94].   
 Plasmodium merozoites have surface proteins which are ideal for inducing 
B-cell antibody production.  One such protein is merozoite surface protein 1 
(MSP 1), a 200 kDa protein essential for RBC invasion by the merozoite.  As this 
protein undergoes a number of proteolytic cleavages, only the highly conserved 
MSP 119 11kDa c-terminal fragment remains on the surface of the merozoite as it 
enters the RBC[95].  As an essential piece of erythrocytic infection that is 
conserved across all Plasmodium species, this protein is an ideal choice against 
which protective antibodies might be produced.   
 Based upon this understanding, a number of studies have demonstrated 
successful protection against blood stage infection in a number of mammalian 
models following immunization with a portion of MSP 1[96-99].  As malaria is a 
disease afflicting predominantly developing countries, it is essential to develop a 
vaccine that can be readily afforded by these populations.  Plant-derived oral 
vaccination makes this possible.  Antigens produced in plants for use as subunit 
vaccines can be delivered without special training, without the need for additional 
instruments such as needles and in the absence of a cold chain.   
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 Previously, our laboratory has demonstrated the stability of such an 
antigen produced in soybean[51].  Soybean is the ideal organism for production 
of antigens of this nature.  Soybean is approximately 40% protein by dry 
weight[52], is readily produced and processed as a food crop and easily stored 
for extended periods of time at ambient temperatures[51, 66].  As protective oral 
immunization has already been demonstrated in the murine model[97], it is 
reasonable to suggest that MSP 1 antigens produced in soybean could be 
administered via transgenic soymilk for the induction of protective antibody titers 
against Plasmodium species. 
4.2 MATERIALS AND METHODS 
Vector design and construction 
The 350bp MSP119 gene containing a native signal peptide sequence, a histidine 
tag sequence, and 5’ and 3’ terminal restriction endonuclease sites was 
optimized for soybean codon usage and synthetically generated by GeneArt, Inc. 
(Burlingame, CA).  Following digestion with NcoI and XbaI, the synthetic gene 
was isolated from an agarose gel and ligated with the binary vector pTN200 that 
had also been linearized with NcoI plus XbaI and gel-isolated.  The resulting 
product, pTN-MSP119, was verified for integrity and transformed into 
Agrobacterium.  The same gene was ligated into the binary vector pTF101, and 
the resulting pTF-MSP119 was verified and transformed. 
A larger fragment of the MSP 1 protein, the MSP 142 gene containing a chitinase 
leader peptide, 6x-histidine tag and KDEL endoplasmic reticulum retention signal 
was optimized and generated in the same manner as the MSP119 genes.  The 
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synthetic gene was, again, digested with NcoI and XbaI, agarose gel purified and 
ligated into the pTN200 binary vector.  The pTN-MSP142 plasmid was verified 
and transformed into Agrobacterium. 
Soybean transformation 
Soybean transformation using the Agrobacterium-mediated half seed method 
was performed as described in Paz et al[69].  Briefly, half-seed explants (G. max 
cv Williams) were dissected and inoculated with Agrobacterium suspension 
culture (strain EHA101 carrying various binary vectors).  The inoculated explants 
were placed adaxial side down on cocultivation medium at 24°C and under 18:6 
photo period for 3-5 days.  After cocultivation, explants were cultured for shoot 
induction and elongation under glufosinate selection (8 mg/L) for 8-12 weeks.  
Herbicide resistant shoots were harvested, elongated and rooted as 
described[69].  Acclimated plantlets were transferred to soil and grown to 
maturity in the greenhouse.   
Recombinant protein production 
The MSP119 gene was PCR amplified with high fidelity Taq polymerase 
(Invitrogen) to replace the NcoI and XbaI restriction sites with XbaI and XhoI, 
respectively.  The PCR product was agarose gel purified and ligated into the 
IPTG inducible expression vector, pET-303 (Invitrogen), which had been 
digested with XbaI and XhoI, then gel purified.  The resulting pET-MSP119 was 
verified for integrity then transformed into the E. coli expression strain, BL21 DE3 
(Invitrogen).  Cells were coated onto luria broth (LB) plates with ampicillin 
(50ug/L) as a marker.  Colonies were picked after 24 hours and incubated 
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overnight in 3 ml LB with ampicillin at 37°C.  Overnight broths were added to 1 
liter of LB with ampicillin and grown to OD280 = 0.6.  1M IPTG was added to 
media, and cultures were incubated for another 12 hours.  Cultures were spun 
down at 8,000g x 45 minutes.  Pellets were resuspended in 1x PBS with .25M 
NaCl and sonicated for 1 minute.  Cultures were centrifuged for 30 minutes at 
8,000g and pellets resuspended in 8M Urea.  Following sonication, cultures were 
rocked at room temperature for 1 hour then spun down to clarify.  Ni2+ column 
resin was added to the supernatant, and protein was purified via the 
manufacturer’s instructions (Sigma-Aldrich). 
Preparation of genomic DNA and PCR 
Genomic DNA was prepared from cotyledon tissue using the Maxwell 16 
Instrument and Maxwell Tissue DNA Purification Kit (Promega, Madison, WI).  
Genomic DNA (100 ng), BAR gene primers (forward: 5’-
TACATCGAGACAAGCACG -3’; reverse: 5’-AGTTCCCGTGCTTGAAGC-3’) and 
dNTPs were mixed with GoTaq Flexi DNA polymerase and buffer (Promega 
Corp., Madison, WI) according to the manufacturer’s directions.  Following an 
initial denaturation cycle (5 minutes at 94°C) the reactions were subjected to 35 
cycles of denaturation (60 seconds at 94°C), annealing (60 seconds at 50°C) and 
extension (120 seconds at 72°C).  440 bp PCR products were visualized in 1.0% 
agarose gels stained with ethidium bromide.  
Seed protein extraction 
Seed slivers (chips) derived from cotyledon tissue (~10 mg) were resuspended in 
200"l PBS and sonicated for ~30 seconds using a Vibra-Cell ultrasonic 
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processor (Newton, CT).  Samples were clarified from soluble debris by 
centrifugation at 16.1 x 103g at 4°C.  Total soluble protein was quantified with the 
Bradford Reagent (Bio-Rad, Hercules,CA) using BSA as a standard.    
Western blot and Dot blot analysis 
For western blots, protein extracts (10"g TSP) from transgenic and wild type 
seeds were run in 12% polyacrylamide gels for approximately 2 hours at 110V.  
Samples were boiled in SDS with #-mercaptoethanol prior to loading onto the 
gel.  Recombinant MSP119 (Sigma, St. Louis, MO) was included for a standard.  
Following electrophoresis, gels were equilibrated in 1X CAPS (recipe for 20X: 
22.13g CAPS, Sigma, in 500ml dH2O, pH 11) buffer with 10% MeOH for 10 
minutes and transferred to Immobilon-P membrane (Millipore, Billerica, MA).  
Membranes were blocked overnight with 5% dry milk in PBS solution at 4°C, 
incubated with mouse anti-MSP 1 monoclonal antibody (Abcam) for ~3 hours at 
23°C, and washed three times (10 minutes each) with PBS containing 0.05% 
Tween.  Membranes were then incubated with goat anti-mouse HRP-conjugated 
IgG (Southern Biotech) for 30 minutes at 23°C and washed as described above.  
Detection was carried out using the SuperSignal West Pico substrate (Thermo 
Scientific, Rockford, IL).   
 For dot blot analysis, Immobilon-P membranes (Millipore, Billerica, MA) 
were equilibrated in 1x CAPS buffer with 10% MeOH for 5 minutes.  Membrane 
was secured to the Bio-Dot Apparatus (BioRad), per the manufacturer’s 
instructions.  40"g TSP of each protein extraction sample and wild type sample 
were loaded onto the membrane via vacuum filtration.  Following membrane 
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removal from the apparatus, protocol continued as described for a western blot 
(see above).  
Preparation of soymilk extracts 
A total of 12 seeds from line ST 95-25 or wild type plants were ground to a fine 
powder.  For each gavage, 475mg of seed powder was resuspended in 3ml of 
phosphate buffered saline (PBS) and sonicated for 1 minute using a Vibra-Cell 
ultrasonic processor (Newton, CT).  Samples were spun at 15,000 rpm for 5 
minutes, and supernatant was transferred to a 1.5ml eppendorf tube.  Tubes 
were spun for an additional 30 seconds at 16.1 x 103g for clarification.   
Oral gavage and sera collection 
Six to eight week old female Balb/c mice were orally immunized three times as 
follows:  using a 22 gauge feeding needle, 200"l of either hTG soymilk protein 
extract containing ~8"g MSP119 or wild type soymilk protein extract was 
administered to each animal on day 0, 5 and 10.  The first immunization was 
given in conjunction with 5"g cholera toxin (CT) as an adjuvant, and the other 
two were given with 10"g CT as an adjuvant.  On days 17 and 23, mice were 
bled (25"l) via the saphenous vein.  Blood was diluted 1:3 in 1x PBS and spun 
down at 8,000g for 10 minutes.  Sera was collected and frozen at -20°C for future 
ELISA analysis. 
ELISA analysis 
ELISA plate was coated with 500ng of recombinant MSP119 overnight at 4°C.  
Plate was then washed with PBS and blocked with 1% BSA-PBS for 1 hour.  
After a second wash, 100"l of sera samples of varying dilutions were loaded on 
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to the plate and incubated at room temperature for 2 hours.  Following a third 
PBS wash, 100"l of anti-mouse IgG-HRP antibody (Southern Biotech) at 1:500 
dilution was added to each well and allowed to incubate for 1 hour.  Following a 
fourth wash, the antibody-antigen complexes were coated with TMB Substrate 
(BioFX, Owings Mills, MD), and colorimetric reactions were stopped by the 
addition of 0.6 M sulfuric acid.  Absorbance values were read at 450nm.  
4.3 RESULTS 
Transformation and Molecular Screening 
MSP 119 has a molecular mass of ~11kDa.  A synthetic gene was designed to 
optimize codon usage as seen in Glycine max.  The gene was cloned 
downstream of the soybean 7S-promotor and a transcription enhancing 
sequence from tobacco etch virus (TEV) to generate pRDP2 (Figure 4.1 and 
Figure 4.2a).  Agrobacterium transformation resulted in two T0 lines, ST 68-6 and 
ST 68-19.  To screen for the presence of the transgene, four T1 seeds from each 
line were subjected to PCR using genomic DNA isolated from seed chips (Figure 
4.4a).  The PCR primers utilized amplified a 440 bp region of the BAR herbicide 
resistance marker cloned alongside the gene of interest.  While PCR evidence 
indicated the seeds were indeed transgenic, western blot analysis failed to 
demonstrate any detectable protein expression (data not shown).  As such, the 
first generation constructs were not pursued further. 
 Using the same synthetic gene, a second construct was made.  The MSP 
119 gene was subcloned downstream of the soybean #-conglycinin promotor and 
a Staphylococcus signal peptide (SEB), which targets the secretory pathway, to 
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generate pRDP4 (Figure 4.1 and Figure 4.2b).  The transformation resulted in 
four transgenic lines:  ST 95-2, 95-3, 95-18 and 95-25.  Eight seeds from each 
line were subjected to PCR as described above to verify the presence of the 
transgene.  It was suspected based on earlier constructs that protein expression 
levels might be extremely low.  Therefore, a dot blot analysis was done in lieu of 
a western blot so as to be able to load additional protein.  As indicated in Figure 
4.5a, only ST 95-25 demonstrated detectable levels of MSP 119.   
 As MSP 119 is a fragment of the larger 200kDa protein MSP 1, we also 
generated the 42 kDa fragment, MSP 142.  As with the other two constructs, the 
gene was optimized for codon usage in Glycine max.  MSP 142 is a membrane 
bound protein secured by a glycosolphosphatidylinosital (GPI) anchor.  As such, 
the synthetic gene was designed to contain a KDEL endoplasmic reticulum 
membrane retention signal in an attempt to optimize expression in a manner 
similar to the protein’s native environment.  The gene was subcloned 
downstream of the soybean derived 7S-promotor, TEV transcription enhancer 
and chitinase leader peptide[52].  Additionally, the GPI anchor was added to the 
gene to improve immunogenicity of the resulting protein[100] (Figure 4.3).  The 
Agrobacterium transformation of pRDP5 (Figure 4.3) yielded extremely low 
numbers of T1 seeds across three lines:  ST 115-4, 115-12 and 115-29. Four 
seeds from each line with the exception of 115-4, which yielded only 2 seeds, 
were analyzed via PCR for the presence of the BAR herbicide resistance marker 
(Figure 4.4c).   
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 Both a dot blot and western blot analysis were done on four seeds from 
each line, when available, as it was believed the changes in the construct would 
increase the expression levels from those seen in pRDP4 (Figure 4.2b).  An anti-
mouse antibody against MSP 1 (the entire protein) was used for detection.  This 
served as a means of detecting the intact MSP 142 protein and any degraded 
fragments that might exist.  No detectable MSP 142 protein or protein fragments 
were observed in either analysis (Figure 4.5b).  
Oral delivery of soybean-derived MSP 119 fails to generate protective antibody 
titers in the murine model.     
ST 95-25 seeds were used to orally immunize Balb/c mice at 0, 5 and 10 days 
(Figure 4.6).  Sera collected from the wild type mouse group and the soy-derived 
MSP 119 mouse group was used to determine antibody titers against recombinant 
MSP 119.  To determine if there was a difference in antibody production between 
the groups, an ELISA was performed.  Figure 4.7 demonstrates that, over the 
course of the experiment, there is no significant difference in antibody titers 
between the wild type and the MSP 119 group.  This suggests the mice that 
received the MSP 119 soymilk formulation did not receive an adequate amount of 
antigen to induce an immune response.  This is unsurprising, considering the low 
expression levels of the transgenic soybeans used. 
4.4 DISCUSSION 
Over the course of this study, three different vector constructs were generated to 
produce optimum protein expression levels (Figures 4.1 and 4.2).  The original 
construct, consisting of the 7S promotor and TEV enhancer (Figure 4.2), no 
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detectable levels of protein were generated.  Using the modified construct with 
the #-conglycinin promoter and no TEV transcription enhancer, extremely low 
levels (~0.01%) of MSP 119 expression were achieved.  Based on previous 
studies that indicated protein retention in the ER improved protein expression[52] 
and studies done in our own lab that indicated the success of our first generation 
construct (unpublished data), a third construct was generated with the 
expectation of improved expression.  While no protein was detactable from this 
third construct, there are a number of possible explanations.  First,  transgene 
expression is not entirely dependent upon construct design.  Other factors 
include position effects, the position of transgene integration in relationship to 
surrounding chromatin, the structure of the locus, as well as copy number and 
the generation of truncated transgene copies.  Together, these factors can inhibit 
protein expression and possibly silence it altogether [45].  Furthermore, the post-
translational modification, particularly glycosylation, in plants varies in pattern 
from other mammals and, of course, does not occur in prokaryotic organisms 
such as Plasmodium.  This difference in protein production can cause dramatic 
changes in protein longevity, inducing its degradation immediately upon 
translation[45, 101].  Additionally, it should be noted that the transformation 
events for the MSP 142 construct produced very limited numbers of T1 seeds.  
Therefore, it is reasonable to suggest that, based upon the poor transformation 
results, the construct and/or protein expressed is, in some manner, toxic to 
Glycine max.   
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Lastly, one should consider the limitation of detection antibodies when drawing 
conclusions of this nature.  We have reported that only one construct of the three 
had produced detectable protein.  This does not mean that the first and third 
generation constructs were unsuccessful, only that the currently available 
antibodies are not sensitive enough to detect the protein that is possibly being 
produced.  While it is logical to address this problem with a replacement 
antibody, the type of antibody in question, against MSP 1, is only available in 
small quantities and from a limited number of commercial sources.  The antibody 
utilized in our studies is the most sensitive of the currently available options.  
Therefore, future studies involving these constructs should consider the 
production of a more robust and sensitive antibody, perhaps generated within our 
laboratory. 
 As only pRDP4 (figure 4.2b) produced detectable levels of protein, these 
seeds were utilized in the murine oral immunization study.  Other laboratories 
have demonstrated successful immunization with oral delivery of MSP 1 and 
other malarial antigens[97].  However, these studies were accomplished with the 
equivalent of 25µg of purified antigen in each dose.  Given the low expression 
levels observed in the transgenic seeds, it was not possible to administer greater 
than 10µg of antigen per gavage.  Furthermore, the additional step required to 
purify the antigen in question serves to render void the economic feasibility of the 
soybean platform and, therefore, was not done.  For these reasons, we were 
unable to induce a protective titer (A450 > 2.0, [97]) in the mouse model.  Despite 
this setback, future studies should progress to establish higher protein 
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expression in the soybean platform that would enable higher doses to be 
administered more frequently in order to establish the antibody titers necessary 
to test via parasite challenge. 
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Figure 4.1 
pRDP2 (pTN-MSP119): 
AAGCTTGCATGCTGCAGGATCCATGCCCTTCATTTGCCGCTTATTAATTAATTTGGTAACAGTCCGTACTAATCAGTTA
CTTATCCTTCCTCCATCATAATTAATCTTGGTAGTCTCGAATGCCACAACACTGACTAGTCTCTTGGATCATAAGAAAA
AGCCAAGGAACAAAAGAAGACAAAACACAATGAGAGTATCCTTTGCATAGCAATGTCTAAGTTCATAAAATTCAAACAA
AAACGCAATCACACACAGTGGACATCACTTATCCACTAGCTGATCAGGATCGCCGCGTCAAGAAAAAAAAACTGGAC
CCCAAAAGCCATGCACAACAACACGTACTCACAAAGGTGTCAATCGAGCAGCCCAAAACATTCACCAACTCAACCCA
TCATGAGCCCTCACATTTGTTGTTTCTAACCCAACCTCAAACTCGTATTCTCTTCCGCCACCTCATTTTTGTTTATTTCA
ACACCCGTCAAACTGCATGCCACCCCGTGGCCAAATGTCCATGCATGTTAACAAGACCTATGACTATAAATATCTGCA
ATCTCGGCCCAGGTTTTCATCATCAAGAACCAGTTCAATATCCTAGTACACCGTATTAAAGAATTTAAGATATACTAAC
AGCGGCCGCTGACACAATAGCCCTTCTTCCCTGTTTCCAGCTTTTCTCCTTCTCTCTCTCTCCATCTTCTTCTTCTTCT
TCACTCAGTCAGATCCAACTCCTCAGATAACACAAGACCAAACCCGCTTTTTCTGCATTGCAAGACTAGACGTTCTAC
CGGAGAAGCGACCTTAGAAATTCATTGCGTTCTCAACACAACATATACAAAACAAACGAATCTCAAGCAATCAAGCAT
TCTACTTCTATTGCAGCAATTTAAATCATTTCTTTTAAAGCAAAAGCAATTTTCTGAAAATTTTCACCATTTACGAACGAT
AGACCATGGATGGAATGGACCTCCTTGGTGTGGACCCTAAACACGTGTGCGTTGATACCAGGGACATACCTAAGAAC
GCTGGATGTTTCCGCGACGATAATGGTACCGAAGAGTGGAGATGCCTTCTCGGTTATAAGAAAGGTGAAGGAAACAC
ATGCGTTGAAAACAATAACCCAACCTGCGACATTAACAACGGTGGATGCGATCCAACCGCATCTTGCCAAAACGCCG
AGAGCACTGAAAACAGCAAGAAGATTATCTGTACTTGTAAGGAGCCTACACCAAACGCCTACTACGAGGGAGTGTTC
TGTAGCAGTAGCAGCGGTGGACACCACCATCACCACCACTGATCTAGAGTCCGCAAAAATCACCAGTCTCTCTCTAC
AAATCTATCTCTCTCTATTTTTCTCCAGAATAATGTGTGAGTAGTTCCCAGATAAGGGAATTAGGGTTCTTATAGGGTT
TCGCTCATGTGTTGAGCATATAAGAAACCCTTAGTATGTATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCTAATT
CCTAAAACCAAAATCCAGTGACCTGGTGGCATGCAAGCTT 
pRDP4 (pTF-MSP119): 
AAGCTTGCATGCCTGCAGGATCCTAGCCTAAGTACGTACTCAAAATGCCAACAAATAAAAAAAAAGTTGCTTTAATAAT
GCCAAAACAAATTAATAAAACACTTACAACACCGGATTTTTTTTAATTAAAATGTGCCATTTAGGATAAATAGTTAATAT
TTTTAATAATTATTTAAAAAGCCGTATCTACTAAAATGATTTTTATTTGGTTGAAAATATTAATATGTTTAAATCAACACAA
TCTATCAAAATTAAACTAAAAAAAAAATAAGTGTACGTGGTTAACATTAGTACAGTAATATAAGAGGAAAATGAGAAATT
AAGAAATTGAAAGCGAGTCTAATTTTTAAATTATGAACCTGCATATATAAAAGGAAAGAAAGAATCCAGGAAGAAAAGA
AATGAAACCATGCATGGTCCCCTCGTCATCACGAGTTTCTGCCATTTGCAATAGAAACACTGAAACACCTTTCTCTTTG
TCACTTAATTGAGATGCCGAAGCCACCTCACACCATGAACTTCATGAGGTGTAGCACCCAAGGCTTCCATAGCCATG
CATACTGAAGAATGTCTCAAGCTCAGCACCCTACTTCTGTGACGTGTCCCTCATTCACCTTCCTCTCTTCCCTATAAAT
AACCACGCCTCAGGTTCTCCGCTTCACAACTCAAACATTCTCTCCATTGGTCCTTAAACACTCATCAGTCATCACCATG
ATGGCAAAGCTCGTGTTCTCTCTTTGCTTCCTTCTTTTCTCCGGATGCTGCTTCGCTTTCTACCATGGATGGAATGGA
CCTCCTTGGTGTGGACCCTAAACACGTGTGCGTTGATACCAGGGACATACCTAAGAACGCTGGATGTTTCCGCGACG
ATAATGGTACCGAAGAGTGGAGATGCCTTCTCGGTTATAAGAAAGGTGAAGGAAACACATGCGTTGAAAACAATAAC
CCAACCTGCGACATTAACAACGGTGGATGCGATCCAACCGCATCTTGCCAAAACGCCGAGAGCACTGAAAACAGCAA
GAAGATTATCTGTACTTGTAAGGAGCCTACACCAAACGCCTACTACGAGGGAGTGTTCTGTAGCAGTAGCAGCGGTG
GACACCACCATCACCACCACTGATCTAGAGTCCGCAAAAATCACCAGTCTCTCTCTACAAATCTATCTCTCTCTATTT
TTCTCCAGAATAATGTGTGAGTAGTTCCCAGATAAGGGAATTAGGGTTCTTATAGGGTTTCGCTCATGTGTTGAGCAT
ATAAGAAACCCTTAGTATGTATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCTAATTCCTAAAACCAAAATCCAGT
GACCTGGTGGCATGCAAGCTT 
pRDP5 (pTN-MSP142): 
ATGGGACCCCAGAAAGAAAACCATAGGACCCTCAACAAGATGAAGACCAACCTTTTCCTCTTCCTCATTTTCTCCCTT
TTGCTTTCTTTGTCATCTGCTGAGCAGCATCATCATCACCATCACGCTATTTCCGTGACTATGGACAACATTCTTTCCG
GATTCGAGAACGAGTACGATGTGATCTACCTTAAGCCACTTGCTGGTGTGTATAGATCTCTCAAGAAGCAGATCGAGA
AGAACATCTTCACCTTCAACCTTAACCTCAACGACATTCTTAACTCCAGGCTCAAGAAGAGAAAGTACTTCCTTGATGT
GCTTGAGTCTGATCTCATGCAGTTCAAGCACATTTCTTCCAACGAGTACATCATCGAGGATTCCTTCAAGTTGCTTAAC
TCCGAGCAAAAGAACACCCTTCTCAAGTCCTACAAGTACATCAAAGAGTCCGTTGAGAACGACATAAGTTCGCTCAAG
AGGGAATTTTCTTACTACGAGAAGGTGCTCGCTAAGTACAAGGATGATCTCGAATCCATTAAGAAGGTGATCAAAGAG
GAAAAAGAGAAGTTCCCATCTTCTCCACCAACTACTCCACCATCTCCAGCTAAGACTGATGAGCAGAAGAAAGAGTCT
AAGTTCCTTCCATTCCTCACCAACATTGAAACCCTCTACAACAACCTCGTGAACAAGATTGATGACTACCTCATCAACC
TCAAGGCTAAGATTAACGATTGCAACGTGGAAAAGGATGAGGCTCATGTGAAGATTACCAAGCTCTCTGATCTCAAG
GCTATCGATGATAAGATCGACCTCTTCAAGAACCCATATGATTTCGAGGCTATCAAGAAGCTCATTAACGACGATACC
AAGAAAGATATGCTCGGAAAGTTGCTTTCTACTGGACTTGTTCAGAACTTCCCCAACACCATTATTTCCAAGCTCATCG
AGGGAAAGTTCCAGGATATGCTCAACATTTCTCAGCATCAGTGCGTTAAGAAGCAATGCCCAGAAAACTCTGGATGCT
TCAGGCATCTTGATGAGAGGGAAGAATGCAAGTGCCTTCTCAACTATAAGGGTGAGGGTGATAAGTGCGTTGAAAAC
CCAAACCCAACTTGCAACGAAAACAACGGTGGATGTGATGCTGATGCTACTTGCACTGAAGAGGATTCTGGATCTTC
CAGGAAGAAGATTACTTGCGAGTGCACTAAGCCAGATTCTTACCCACTCTTCGATGGAATTTTCTGCTCCTCTTCCAA
CTTCCTTGGAATTTCCTTCCTCCTCATCCTTATGCTTATCCTCTACTCCTTCATCAAGGACGAGCTGTGATAATCTAGA 
 
Figure 4.1: Plasmodium construct sequences.  pRDP2 is the DNA sequence cloned into the pTN 
vector backbone for the first generation malarial constructs (Figure 4.2)  pRDP4 is the sequence 
for the second generation pTF vector construct and pRDP5 indicates the sequence changes 
made for the third and final generation construction in the pTN vector backbone. 
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Figure 4.2 
 
 
Figure 4.2:  Gene design and soybean transformation.  A. Binary vector pTN-
MSP119 (pRDP2) used for Agrobacterium transformation with the following 
elements:  7S-promotor, tobacco etch virus (TEV) translational enhancer, 
MSP119 synthetic gene, cauliflower mosaic virus terminator (T-35S) nopaline 
synthase promotor (Nos-p), phosphinothricin acetyltransferase gene for selection 
(Bar ORF), Nos terminator element, right border (RB) and left border (LB).  B. 
Binary vector pTF-MSP119 (pRDP4) used for Agrobacterium transformation, 
modified from the original pRDP2 with the following: soybean Glycinin promotor, 
SEB signal peptide targeting secretory pathway and removal of TEV element. 
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Figure 4.3 
 
 
 
 
 
 
 
 
Figure 4.3:  Second generation gene design and soybean transformation.  Binary 
vector pTN-MSP142 (pRDP5) used for Agrobacterium transformation with the 
following elements:  7S-soybean #-conglycinin promotor, tobacco etch virus 
(TEV) translational enhancer, chitinase leader peptide for targeting to the 
endoplasmic reticulum, MSP142 synthetic gene, KDEL endoplasmic reticulum 
retention signal, cauliflower mosaic virus terminator (T-35S) nopaline synthase 
promotor (Nos-p), phosphinothricin acetyltransferase gene for selection (Bar 
ORF), Nos terminator element, right border (RB) and left border (LB).   
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Figure 4.4 
 
 
 
 
Figure 4.4: PCR analysis of transgenic soybean seeds to confirm transgenicity. 
A. pTN-MSP119 PCR analysis detecting Bar ORF in genomic DNA isolated from 
T1 seed chips.  Amplified PCR product migrates at 440 base pairs (bp).  Genomic 
DNA from wild type plant  is designated as the negative control (-), and the 
positive control (+) is pTN-MSP119 plasmid DNA.  B. pTF-MSP119 PCR analysis 
detecting Bar ORF in genomic DNA isolated from T1 seed chips.  Amplified PCR 
product migrates at 440bp.  Genomic DNA from wild type plant  is designated as 
the negative control (-).  C. pTN-MSP142 PCR analysis detecting Bar ORF in 
genomic DNA isolated from T1 seed chips.   
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Figure 4.5 
 
 
 
 
 
Figure 4.5: Dot blot and western blot soybean analysis.  A. Dot blot analysis of 
pTF-MSP119 seeds.  Top panel is western blot, indicating, via MSP 1 antibody, 
those seeds expressing protein at ~0.01% TSP.  Bottom panel is the coomassie 
stain of the western membrane, demonstrating protein loading, specifically wild 
type (WT).  B. Western blot analysis of pTN-MSP142 seeds with wild type (WT) 
control.  Protein of interest should run at 42 kDa, as indicated by the arrows.  No 
detectable protein is present.  (TSP = total soluble protein)  
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Figure 4.6 
 
 
Figure 4.6: Plasmodium Oral Immunization Schedule:  Six to eight week old 
balb/c mice were pre-bled one day prior to the beginning of the immunization 
regimen.  On day 0, 5 and 10, mice in both the MSP and WT group were 
gavaged with 200ul soybean formulation.  One and two weeks following the final 
immunization, mice were bled for sera antibody titer detection. 
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Figure 4.7 
 
 
 
 
 
 
Figure 4.7:  MSP119 ELISA to determine antibody titers.  Sera from wild type and 
MSP mice was taken at day zero (PB), 7 and 14.  Sera was analyzed via ELISA 
to determine if there was a difference between the groups in terms of MSP119 
antibody titers.  Absorbance was measured at 450nm.  One way analysis of 
variance (ANOVA) indicated no statistical difference at any point in the 
experiment. 
MSP 119 Antibody Titers 
CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
 
The cost of production and safety concerns surrounding traditional vaccines has 
led the scientific community to search for new methods of vaccine administration.  
Mucosal immunology has generated an interest in oral antigen delivery.  The 
majority of an individual’s immune response is localized in the gut mucosa, and 
the response generated there leads not only to a common response at all 
mucosal surfaces but also to a systemic response.  Furthermore, while 
vaccination is of interest, such a delivery mechanism could be used to initiate 
tolerance responses to particular antigens, abrogating difficulties with 
autoimmune disorders and allergies.   
 Our laboratory is currently exploring the production of a soybean-based 
delivery platform for subunit vaccines and tolerogens.  Edible therapies are, in 
general, an ideal means of delivering oral therapeutics.  However, many plants 
currently being explored for this process are deficient in protein expression, 
difficult to store long term and require special processes such as flash freezing to 
maintain protein stability during transportation.  Soybean, however, is 
approximately 40% protein and, as antigens can be directed to express in the 
seed, can be stored indefinitely at ambient temperatures.  Furthermore, the 
production of soymilk for consumption is well established, and the same 
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processes can be utilized to produce soymilk from transgenic seeds for 
therapeutic delivery.   
 In the studies outlined in previous chapters, our laboratory has examined 
antigens for both tolerance and immunization.  Human thyroglobulin (hTG) is one 
of the primary auto-antigens in the establishment of Hashimoto’s hypothyroiditis 
(HT).  This protein is used in diagnostic assays to determine the presence of 
autoantibodies in patients suspected of having HT.  The only currently available 
source of thyroglobulin is from cadaver tissue.  The means of extracting 
thyroglobulin and testing it for contaminants and pathogens is extremely 
expensive and inefficient, driving up the cost of the assay for the thousands of 
individuals diagnosed with HT each year.  Additionally, the only currently 
treatment for HT is lifelong hormone replacement therapy with levothyroxine, the 
synthetic form of thyroglobulin.   
 Our laboratory was able to express human thyroglobulin at ~ 1.0% TSP in 
soybeans.  This success creates a second source for a very important 
pharmacological protein.  More importantly, this source of protein is cost effective 
and easily reproducible.  Since expression has been established, future studies 
should focus on further analytical verification of the soybean-derived protein.  
Although partial purification has been achieved, further analysis to purify the 
protein for use in diagnostics is required.  In addition, focus should be placed on 
the establishment of a column device to remove autoantibodies that interfere with 
thyroid cancer assays and generate false negative results. 
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 Despite the myriad applications for hTG in diagnostics, our laboratory has 
also placed an emphasis on initiating a tolerance response to the antigen in an 
attempt to inhibit HT disease induction and progression.  In these studies, we 
demonstrate successful inhibition of hTG antibody production in the murine 
model.    As this is the diagnostic hallmark of disease, it is reasonable to 
conclude that disease inhibition could be achieved via oral delivery of soybean-
derived hTG.  Future studies will focus on the time course and dose of therapy 
required to completely inhibit disease progression, examine the pathology of 
murine thyroids in relationship to disease inhibition or lack thereof and determine 
T3 and T4 hormone levels in mice that have been successfully tolerized as 
indicated by other markers.  If successful, these studies could demonstrate an 
alternative to traditional hormone replacement therapy and offer a more cost-
effective, permanent one time therapy for individuals at risk for HT or in the early 
stages of disease onset. 
 Given our success with tolerance induction using the soybean platform, 
our studies expanded to examine the production of malarial antigens in soybean 
for oral vaccination.  We designed three constructs for transformation into 
soybean, producing only one that successfully expressed the MSP 119 protein in 
the soybean platform.  Our analysis indicated extremely low levels of expression 
(~0.01%).  The potential reasons for this are varied and will require additional 
analysis of the transgenic soybeans, including southern blot analysis to test for 
position effects and multi-copy insertions.   
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 Using the positively expressing seeds, a small murine study was 
conducted to determine if protective titers against MSP 119 could be established.  
Given the low levels of antigen expression, it is unsurprising that this study was 
not successful.  Second generation experiments should be conducted only when 
expression levels of 0.5-1.0% have been achieved, making it possible to 
administer greater doses of antigen via oral gavage.   
 Taken together, these experiments indicate the extreme versatility of the 
soybean platform.  Numerous options are available for construct design, protein 
expression and commercial applications.  Once optimized, the soybean platform 
will offer a cost effective, reproducible and readily obtainable alternative to 
diagnostic analytes and pharmacological therapeutics.   
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